Piotr Ponikowski

Q: What Schools Are Affiliated With Piotr Ponikowski

Piotr Ponikowski is affiliated with the following schools: Imperial College London, Wrocław Medical University, Virginia Commonwealth University, RWTH Aachen University, University of Groningen, Columbia University, University of Auckland, Maastricht University, Duke University

Piotr Ponikowski's AcademicInfluence.com Rankings

Piotr Ponikowski

Medical

#476

World Rank

#652

Historical Rank

Cardiology

#21

World Rank

#21

Historical Rank

medical Degrees

Piotr Ponikowski

Philosophy

#3345

World Rank

#5417

Historical Rank

Logic

#1100

World Rank

#1746

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Piotr Ponikowski Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Piotr Ponikowski is a Polish cardiologist, Professor of Medical Sciences, Vice-Rector of the Wrocław Medical University and Head of the Polish Cardiological Society . His scientific interests include research on heart failure, coronary heart disease and heart arrhythmia.

(See a Problem?)

Piotr Ponikowski's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

[2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. (2016) (7627)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2016) (6692)
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). (2013) (6036)
ESC / EACTS Guidelines on myocardial revascularization (2012) (5643)
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. (2016) (5626)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016) (4929)
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 (2010) (4824)
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). (2010) (4221)
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. (2013) (3723)
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). (2010) (3518)
2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous (2014) (3302)
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). (2007) (3077)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. (2019) (2915)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016) (2451)
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). (2013) (2221)
Cachexia: a new definition. (2008) (1968)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. (2020) (1835)
Ferric carboxymaltose in patients with heart failure and iron deficiency. (2009) (1586)
Wasting as independent risk factor for mortality in chronic heart failure (1997) (1299)
2015 ESC Guidelines for the diagnosis and management of pericardial diseases (2015) (1246)
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. (2006) (1170)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. (2021) (1081)
2018 ESC Guidelines for the diagnosis and management of syncope (2018) (942)
Heart failure: preventing disease and death worldwide (2014) (941)
2016 European Guidelines on cardiovascular disease prevention in clinical practice (2012) (904)
Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative (2009) (874)
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency† (2014) (837)
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial (2013) (834)
The 2013 ESH/ESC guidelines for the management of arterial hypertension (2013) (805)
Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. (1997) (799)
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines (2016) (738)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. (2020) (736)
EURObservational Research Programme: regional differences and 1‐year follow‐up results of the Heart Failure Pilot Survey (ESC‐HF Pilot) (2013) (694)
Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. (2009) (694)
How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). (2019) (687)
Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation (2011) (612)
Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine (2010) (596)
Uric Acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging (2003) (584)
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long‐Term Registry (2013) (577)
Corrigendum to: ‘Guidelines for the management of atrial fibrillation’ [European Heart Journal (2010) 31, 2369–2429 and EP-Europace (2010) 12, 1360–1420] (2011) (570)
Nutritional recommendations for the management of sarcopenia. (2010) (564)
Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. (1997) (542)
Iron deficiency: an ominous sign in patients with systolic chronic heart failure. (2010) (536)
Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the Europe (2010) (520)
Iron deficiency in chronic heart failure: an international pooled analysis. (2013) (519)
Effect of nesiritide in patients with acute decompensated heart failure. (2011) (516)
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. (2020) (512)
Warfarin and aspirin in patients with heart failure and sinus rhythm. (2012) (511)
Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. (2007) (508)
Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. (1997) (502)
Cardiovascular Efficacy and Safety of Bococizumab in High‐Risk Patients (2017) (488)
Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. (2010) (485)
213 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy (2013) (484)
Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology (2009) (484)
Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. (2010) (478)
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology (2019) (469)
Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO2slope and peak VO2 (2000) (448)
Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study (2009) (412)
Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. (2013) (411)
Enhanced Ventilatory Response to Exercise in Patients With Chronic Heart Failure and Preserved Exercise Tolerance: Marker of Abnormal Cardiorespiratory Reflex Control and Predictor of Poor Prognosis (2001) (408)
Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. (2007) (398)
Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. (1997) (398)
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure (2021) (395)
EURObservational Research Programme: The Heart Failure Pilot Survey (ESC‐HF Pilot) (2010) (395)
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology (2011) (380)
Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors (2020) (379)
Anabolic Deficiency in Men With Chronic Heart Failure: Prevalence and Detrimental Impact on Survival (2006) (378)
Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology (2007) (374)
Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. (1999) (370)
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial (2013) (362)
Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III (2005) (328)
Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial (2016) (324)
Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives (2012) (324)
Recommendations on pre‐hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine (2015) (323)
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology (2009) (319)
Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial (2009) (292)
Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron‐deficient heart failure patients: an individual patient data meta‐analysis (2018) (289)
Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study (2017) (288)
Adherence of heart failure patients to exercise: barriers and possible solutions (2012) (283)
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial (2020) (280)
Peripheral Chemoreceptor Hypersensitivity: An Ominous Sign in Patients With Chronic Heart Failure (2001) (278)
Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure. (1997) (276)
Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. (2008) (268)
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. (2020) (266)
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. (2020) (265)
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. (2015) (264)
Diuretic response in acute heart failure: clinical characteristics and prognostic significance. (2013) (263)
Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. (2021) (263)
Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. (2005) (260)
Effects of intravenous iron therapy in iron‐deficient patients with systolic heart failure: a meta‐analysis of randomized controlled trials (2016) (258)
Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency (2017) (255)
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study (2017) (251)
Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (2017) (248)
Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice: Insight From the Real-Life Global Survey Evaluating Patients With Atrial Fibrillation International Registry (2012) (245)
Muscle Ergoreceptor Overactivity Reflects Deterioration in Clinical Status and Cardiorespiratory Reflex Control in Chronic Heart Failure (2001) (240)
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease (2016) (240)
Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure (2010) (239)
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. (2007) (233)
Improving care for patients with acute heart failure: before, during and after hospitalization (2014) (232)
A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF) (2019) (226)
A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF) (2019) (226)
Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. (2011) (218)
Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO(2)slope and peak VO(2). (2000) (218)
Oscillatory breathing patterns during wakefulness in patients with chronic heart failure: clinical implications and role of augmented peripheral chemosensitivity. (1999) (216)
Iron status in patients with chronic heart failure. (2013) (216)
Iron deficiency and cardiovascular disease (2015) (212)
Experience from controlled trials of physical training in chronic heart failure. Protocol and patient factors in effectiveness in the improvement in exercise tolerance. European Heart Failure Training Group. (1998) (210)
Corrigendum to ‘ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008’ [Eur Heart J 2008;29:2388–2442 and Eur J Heart Fail 2008;10:933–989] (2009) (208)
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial (2016) (200)
A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. (2007) (196)
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction (2019) (195)
Physicians' adherence to guideline‐recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey (2016) (193)
Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. (2010) (192)
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document (2013) (183)
Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches (2011) (182)
Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. (2016) (182)
Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. (2014) (178)
Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry (2017) (177)
Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure (2017) (175)
The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction. (2015) (174)
Iron Deficiency in Heart Failure: An Overview. (2019) (168)
Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. (2018) (167)
Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy (2019) (165)
The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. (2013) (162)
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (2022) (160)
How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) (2020) (158)
Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II (2008) (158)
A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT‐CHF (2016) (157)
Relation of heart rate and blood pressure turbulence following premature ventricular complexes to baroreflex sensitivity in chronic congestive heart failure. (2001) (156)
Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonar (2016) (156)
Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated Copeptin: Secondary Results From the Biomarkers in Acute Heart Failure (BACH) Study (2011) (156)
Home telemonitoring in heart failure patients: the HHH study (Home or Hospital in Heart Failure) (2009) (154)
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial (2008) (152)
Signature of circulating microRNAs in patients with acute heart failure (2016) (152)
Effect of anemia on exercise tolerance in chronic heart failure in men. (2003) (150)
Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. (2007) (150)
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status (2020) (150)
Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. (2003) (150)
ESPEN Guidelines on Enteral Nutrition: Cardiology and pulmonology. (2006) (149)
Reduced Peripheral Skeletal Muscle Mass and Abnormal Reflex Physiology in Chronic Heart Failure (2006) (148)
The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors (2017) (144)
Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine--short version. (2015) (144)
Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. (2014) (144)
The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics (2019) (144)
Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo‐controlled trial (2017) (143)
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction (2020) (142)
Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes: Lessons Learned and Directions Forward (2010) (141)
The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study (2012) (141)
Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial (2012) (140)
Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. (1997) (140)
Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial (2013) (138)
Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo‐controlled trial (2015) (137)
A neural link to explain the "muscle hypothesis" of exercise intolerance in chronic heart failure. (1999) (136)
Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM) (2017) (134)
Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from RELAX-AHF (2014) (133)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. (2017) (132)
Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial. (2018) (132)
Mid‐regional pro‐adrenomedullin as a novel predictor of mortality in patients with chronic heart failure (2010) (132)
Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decom (2011) (131)
Effects of Serelaxin in Patients with Acute Heart Failure. (2019) (129)
The clinical significance of interleukin‐6 in heart failure: results from the BIOSTAT‐CHF study (2019) (128)
2010 Focused Update of ESC Guidelines on device therapy in heart failure (2010) (128)
Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. (2018) (126)
Autonomic imbalance and immune activation in chronic heart failure - pathophysiological links. (2006) (126)
Transvenous phrenic nerve stimulation for the treatment of central sleep apnoea in heart failure. (2012) (126)
Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology (2018) (125)
Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES) (2014) (125)
Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry (2011) (124)
Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). (2010) (124)
Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. (2011) (123)
Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. (2008) (123)
Phrenic nerve stimulation for the treatment of central sleep apnea. (2015) (122)
Acute heart failure congestion and perfusion status – impact of the clinical classification on in‐hospital and long‐term outcomes; insights from the ESC‐EORP‐HFA Heart Failure Long‐Term Registry (2019) (121)
Acute heart failure congestion and perfusion status – impact of the clinical classification on in‐hospital and long‐term outcomes; insights from the ESC‐EORP‐HFA Heart Failure Long‐Term Registry (2019) (121)
Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. (2020) (120)
Clinical characteristics of chronic heart failure patients with an augmented peripheral chemoreflex. (1997) (119)
Mechanisms and clinical consequences of untreated central sleep apnea in heart failure. (2015) (119)
Soluble guanylate cyclase: a potential therapeutic target for heart failure (2013) (118)
The PROTECT in‐hospital risk model: 7‐day outcome in patients hospitalized with acute heart failure and renal dysfunction (2012) (118)
Effect of estrogen replacement therapy on heart rate variability and heart rate in healthy postmenopausal women. (1997) (117)
Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial (2016) (116)
Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference. (2010) (116)
Rationale and design of Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia (2009) (114)
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure (2019) (114)
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy (2020) (114)
Contribution of skeletal muscle ‘ergoreceptors’ in the human leg to respiratory control in chronic heart failure (2000) (113)
Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX‐AHF study (2015) (111)
Guidelines for the management of atrial fibrillation (Europace (2010) 12, (1360-1420)) (2011) (111)
EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM (2014) (110)
A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure (2013) (110)
Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). (2013) (107)
Predicting heart failure outcome from cardiac and comorbid conditions: the 3C-HF score. (2013) (106)
Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure (2019) (106)
Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. (2018) (105)
Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology (2018) (104)
Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients. (2006) (103)
Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study (2017) (103)
Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa on hemoglobin response and symptoms in patients with heart failure and anemia (2006) (103)
Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre‐RELAX‐AHF (2011) (103)
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology (2021) (102)
Circadian pattern of heart rate variability in chronic heart failure patients. Effects of physical training. (1995) (101)
The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications (2016) (100)
The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology (2017) (100)
The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure. (2016) (99)
The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study (2010) (98)
Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure: Analysis From the PROTECT Pilot Study (2011) (97)
Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study (2010) (96)
Abnormal autonomic control of the cardiovascular system in syndrome X. (1994) (95)
Circulating estradiol and mortality in men with systolic chronic heart failure. (2009) (93)
Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated CopeptinClinical Perspective (2011) (92)
Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial (2013) (91)
Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. (2009) (91)
[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. (2007) (91)
Treatments targeting inotropy. (2018) (91)
Carotid body removal for treatment of chronic systolic heart failure. (2013) (91)
One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction (2016) (90)
CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how? (2018) (90)
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. (2021) (90)
Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. (2007) (89)
Management of heart failure patients with COVID‐19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology (2020) (89)
Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. (2014) (88)
Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF) (2017) (88)
Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. (2011) (88)
Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS (2017) (86)
Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology (2020) (85)
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. (2020) (84)
Thrombo‐embolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis (2012) (83)
A multimarker multi‐time point‐based risk stratification strategy in acute heart failure: results from the RELAX‐AHF trial (2017) (83)
Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF) (2010) (83)
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial (2021) (83)
Thrombo‐embolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis (2012) (83)
Growth differentiation factor 15 (GDF‐15) in patients admitted for acute heart failure: results from the RELAX‐AHF study (2015) (83)
Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. (2009) (82)
Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. (2017) (82)
Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. (2010) (82)
Optimizing clinical use of biomarkers in high‐risk acute heart failure patients (2016) (82)
Physicians' guideline adherence is associated with long‐term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry (2019) (80)
Prognostic value of changes over time in exercise capacity and echocardiographic measurements in patients with chronic heart failure. (2000) (80)
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age (2019) (80)
Waist‐to‐hip ratio and mortality in heart failure (2018) (79)
Carotid body resection for sympathetic modulation in systolic heart failure: results from first‐in‐man study (2017) (78)
Predictors of Post-Discharge Outcomes from Information Acquired Shortly After Admission for Acute Heart Failure: A Report from the PROTECT Study (2013) (78)
Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT‐CHF (2017) (77)
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study‐Heart Failure (ARTS‐HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease (2015) (77)
Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure (2016) (77)
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. (2020) (76)
Short-term mortality risk in emergency department acute heart failure. (2011) (76)
Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). (2015) (75)
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF (2021) (75)
Patient‐reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES‐PRESERVED) study (2017) (75)
The 12-week progressive quadriceps resistance training improves muscle strength, exercise capacity and quality of life in patients with stable chronic heart failure. (2008) (75)
International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short‐term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial (2014) (74)
Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies (2015) (74)
Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency (2012) (74)
N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. (2020) (74)
Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones (2014) (73)
Chronic heart failure in the elderly: value of cardiopulmonary exercise testing in risk stratification (2000) (73)
Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure (2015) (73)
The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. (2000) (72)
Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm (2012) (72)
Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups (2013) (72)
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF) (2020) (72)
Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role (2014) (71)
Design of the RELAXin in acute heart failure study. (2012) (70)
Rationale and design of ARTS: a randomized, double‐blind study of BAY 94‐8862 in patients with chronic heart failure and mild or moderate chronic kidney disease (2012) (70)
Ventilatory response to exercise correlates with impaired heart rate variability in patients with chronic congestive heart failure. (1998) (70)
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial (2020) (70)
Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure (2020) (69)
Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion (2018) (69)
Telerehabilitation in heart failure patients: The evidence and the pitfalls. (2016) (68)
Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. (2016) (68)
What have we learned about heart failure with mid‐range ejection fraction one year after its introduction? (2017) (68)
Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF (2013) (67)
Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. (2007) (66)
Association with outcomes and response to treatment of trimethylamine N‐oxide in heart failure: results from BIOSTAT‐CHF (2018) (65)
Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure (2016) (65)
Contribution of peripheral chemoreceptors to ventilation and the effects of their suppression on exercise tolerance in chronic heart failure. (1996) (65)
ExtraHF survey: the first European survey on implementation of exercise training in heart failure patients (2015) (64)
The additive burden of iron deficiency in the cardiorenal–anaemia axis: scope of a problem and its consequences (2014) (63)
Detection and significance of a discrete very low frequency rhythm in RR interval variability in chronic congestive heart failure. (1996) (62)
Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60‐day outcomes in the PROTECT pilot study (2010) (62)
Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study (2016) (62)
Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure (2013) (61)
Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure (2014) (61)
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) (2020) (61)
Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure (2018) (61)
Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. (2012) (60)
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. (2021) (59)
Iron deficiency as energetic insult to skeletal muscle in chronic diseases (2018) (59)
Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. (2014) (59)
Aetiology and pathophysiological implications of oscillatory ventilation at rest and during exercise in chronic heart failure. Do Cheyne and Stokes have an important message for modern-day patients with heart failure? (1999) (58)
Potassium and the use of renin–angiotensin–aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT‐CHF (2018) (58)
ESPEN Guidelines on Parenteral Nutrition: on cardiology and pneumology. (2009) (58)
Guía ESC 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica (2016) (58)
In‐hospital worsening heart failure (2015) (57)
Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction (2020) (57)
Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. (2020) (57)
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial (2021) (56)
Impaired hepato‐renal function defined by the MELD XI score as prognosticator in acute heart failure (2016) (56)
Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion: A Post Hoc Analysis of the PROTECT Data (2018) (55)
Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure: Rationale and Design of the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I) (2016) (55)
Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK (2012) (55)
Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants (2009) (54)
A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure (2017) (54)
Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial (2019) (54)
Distance covered during a six-minute walk test predicts long-term cardiovascular mortality and hospitalisation rates in men with systolic heart failure: an observational study. (2013) (54)
Guías de práctica clínica para el manejo de la fibrilación auricular (2010) (53)
Chemoreceptor dependence of very low frequency rhythms in advanced chronic heart failure. (1997) (53)
Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) (2020) (53)
Sex‐specific acute heart failure phenotypes and outcomes from PROTECT (2013) (52)
Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure (2017) (52)
Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial (2016) (52)
Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial. (2016) (52)
Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure (2019) (51)
Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease. (2010) (50)
Dissociation between blood pressure and heart rate response to hypoxia after bilateral carotid body removal in men with systolic heart failure (2014) (50)
Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. (2016) (50)
Guía de práctica clínica de la sociedad europea de cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008) (2008) (50)
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study (2011) (49)
Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. (2018) (49)
Patient journey after admission for acute heart failure: length of stay, 30‐day readmission and 90‐day mortality (2016) (49)
Effect of Ejection Fraction on Clinical Outcomes in Patients treated with Omecamtiv Mecarbil in GALACTIC-HF. (2021) (49)
Physician-Determined Worsening Heart Failure: A Novel Definition for Early Worsening Heart Failure in Patients Hospitalized for Acute Heart Failure – Association with Signs and Symptoms, Hospitalization Duration, and 60-Day Outcomes (2009) (48)
Predictors of early dyspnoea relief in acute heart failure and the association with 30‐day outcomes: findings from ASCEND‐HF (2013) (48)
Chemosensitivity in chronic heart failure. (2001) (48)
Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies. (2015) (48)
Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study (2012) (47)
Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction (2018) (46)
Origin of oscillatory kinetics of respiratory gas exchange in chronic heart failure. (1999) (46)
Design of the remedē System Pivotal Trial: A Prospective, Randomized Study in the Use of Respiratory Rhythm Management to Treat Central Sleep Apnea. (2015) (46)
Molecular changes in myocardium in the course of anemia or iron deficiency. (2010) (46)
Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners (2016) (45)
Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial (2021) (45)
Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe (2020) (45)
Rationale and design of the CONFIRM‐HF study: a double‐blind, randomized, placebo‐controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency (2014) (45)
Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure. (1998) (45)
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials (2020) (44)
Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial (2015) (43)
Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction (2018) (43)
Transvenous stimulation of the phrenic nerve for the treatment of central sleep apnoea: 12 months' experience with the remedē® System (2016) (42)
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF (2020) (42)
Silver paper: The future of health promotion and preventive actions, basic research, and clinical aspects of age-related disease (2009) (42)
Trimetazidine in cardiovascular medicine. (2019) (41)
Identification of Chronic Heart Failure Patients with a High 12-Month Mortality Risk Using Biomarkers Including Plasma C-Terminal Pro-Endothelin-1 (2011) (41)
Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials). (2017) (41)
The impact of cachexia on cardiorespiratory reflex control in chronic heart failure. (1999) (41)
Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment (2019) (41)
Cardiac autonomic dysfunction in AIDS is not secondary to heart failure. (2000) (41)
Corrigendum to '2017 ESC/EACTS Guidelines for the management of valvular heart disease' [Eur J Cardiothorac Surg 2017;52:616-664]. (2017) (39)
Resting and exercise haemodynamics in relation to six‐minute walk test in patients with heart failure and preserved ejection fraction (2018) (39)
Clinical predictors and hemodynamic consequences of elevated peripheral chemosensitivity in optimally treated men with chronic systolic heart failure. (2013) (39)
Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF. (2018) (39)
Effect of altering conditions of the sequence method on baroreflex sensitivity (2001) (39)
Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure (2019) (38)
MicroRNAs relate to early worsening of renal function in patients with acute heart failure. (2016) (38)
Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure (2019) (38)
ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference. (2010) (38)
Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial (2021) (38)
Liver function tests in patients with acute heart failure. (2012) (38)
A combined clinical and biomarker approach to predict diuretic response in acute heart failure (2015) (38)
Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. (2017) (38)
2016 ESC and ACC/AHA/HFSA heart failure guideline update — what is new and why is it important? (2016) (38)
Impaired baroreflex sensitivity and sympathovagal balance in syndrome X. (1998) (37)
Deficiencies in circulating testosterone and dehydroepiandrosterone sulphate, and depression in men with systolic chronic heart failure (2010) (37)
Guía ESC/EACTS 2017 sobre el tratamiento de las valvulopatías (2018) (37)
The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure (2009) (36)
Patogenia y presentación clínica de la insuficiencia cardiaca aguda (2015) (36)
Comparison of invasive and non-invasive measurements of haemodynamic parameters in patients with advanced heart failure (2011) (36)
Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. (2019) (36)
Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure (2017) (36)
The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina (2012) (36)
Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction (2020) (36)
Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure (2016) (36)
Hyperhomocysteinemia in patients with symptomatic chronic heart failure: prevalence and prognostic importance--pilot study. (2007) (36)
Comparison between spectral analysis and the phenylephrine method for the assessment of baroreflex sensitivity in chronic heart failure. (1999) (36)
The association of lower testosterone level with coronary artery disease in postmenopausal women. (2003) (36)
The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis. (2017) (36)
Home telemonitoring of vital signs and cardiorespiratory signals in heart failure patients: system architecture and feasibility of the HHH model. (2007) (36)
Bone marrow iron depletion is common in patients with coronary artery disease. (2015) (36)
Anemia in chronic heart failure: Can we treat? What to treat? (2012) (35)
Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). (2009) (35)
Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: Findings From the EVEREST Trial (2014) (35)
Depleted iron stores are associated with inspiratory muscle weakness independently of skeletal muscle mass in men with systolic chronic heart failure (2018) (35)
Silver paper: the future of health promotion and preventive actions, basic research, and clinical aspects of age-related disease--a report of the European Summit on Age-Related Disease. (2009) (35)
Iron deficiency and red cell indices in patients with heart failure (2018) (35)
Pathogenesis and clinical presentation of acute heart failure. (2015) (35)
Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure-results from the relaxin for the treatment of patients with acute heart failure study. (2014) (35)
Rationale for and design of the TRUE‐AHF trial: the effects of ularitide on the short‐term clinical course and long‐term mortality of patients with acute heart failure (2017) (35)
Novel endotypes in heart failure: effects on guideline-directed medical therapy (2018) (35)
Reproducibility of heart rate variability measures in patients with chronic heart failure. (1996) (34)
Worsening Renal Function in Acute Heart Failure (2009) (34)
High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality (2020) (34)
Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis. (2013) (34)
Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS‐III (2004) (34)
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial (2022) (34)
Rationale and design of the AFFIRM‐AHF trial: a randomised, double‐blind, placebo‐controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron‐deficient patients admitted for acute heart failure (2019) (33)
Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction † (2013) (33)
Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF (2020) (33)
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) (2013) (33)
Changes in autonomic balance in patients with decompensated chronic heart failure (2011) (33)
Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. (2016) (33)
Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. (2010) (33)
Could the two-minute step test be an alternative to the six-minute walk test for patients with systolic heart failure? (2016) (32)
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. (2021) (32)
Consequences of peripheral chemoreflex inhibition with low‐dose dopamine in humans (2014) (32)
Transient autonomic dysfunction precedes ST-segment depression in patients with syndrome X. (1996) (32)
The year in cardiology 2018: heart failure (2019) (31)
Effectiveness of screening for atrial fibrillation and its determinants. A meta-analysis (2019) (31)
Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid‐range and preserved ejection fraction (2017) (31)
The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment (2012) (31)
Polypill Strategy in Secondary Cardiovascular Prevention. (2022) (31)
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction (2021) (30)
Effects of amiodarone on the P-wave triggered signal-averaged electrocardiogram in patients with paroxysmal atrial fibrillation and coronary artery disease. (1999) (30)
Effect of dapagliflozin on anaemia in DAPA‐HF (2021) (30)
Efficacy and safety of sodium–glucose co‐transporter 2 inhibition according to left ventricular ejection fraction in DAPA‐HF (2020) (30)
The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH UP study. (2010) (29)
Long-term efficacy and safety of phrenic nerve stimulation for the treatment of central sleep apnea (2019) (29)
Exercise programs for LVAD supported patients: A snapshot from the ESC affiliated countries. (2015) (29)
Benefit of Warfarin Compared With Aspirin in Patients With Heart Failure in Sinus Rhythm: A Subgroup Analysis of WARCEF, a Randomized Controlled Trial (2013) (29)
Plasma kidney injury molecule‐1 in heart failure: renal mechanisms and clinical outcome (2016) (29)
Hyperkalemia and Treatment With RAAS-Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. (2019) (28)
Structural and functional abnormalities in iron-depleted heart (2018) (28)
Effects of ivabradine in patients with stable angina receiving β-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. (2013) (28)
A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain. (2015) (28)
Multi‐organ dysfunction/injury on admission identifies acute heart failure patients at high risk of poor outcome (2019) (27)
Rationale and design of a multicentre, randomized, placebo‐controlled trial of mirabegron, a Beta3‐adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3‐left ventricular hypertrophy (Beta3‐LVH) (2018) (27)
Heart rhythms, ventricular arrhythmias, and death in chronic heart failure. (1996) (27)
Very-low-frequency oscillations in heart rate and blood pressure in periodic breathing: role of the cardiovascular limb of the hypoxic chemoreflex. (2000) (27)
Clinical value of pre‐discharge bio‐adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission (2019) (27)
Recurrent Stroke in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial (2014) (26)
Normal electrocardiographic and echocardiographic (M-mode and two-dimensional) values in Polish Landrace pigs (2014) (26)
Health locus of control and the sense of self-efficacy in patients with systolic heart failure: a pilot study (2013) (26)
Controlled decongestion by Reprieve therapy in acute heart failure: results of the TARGET‐1 and TARGET‐2 studies (2019) (26)
The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR‐HF study (2013) (25)
Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review. (2021) (25)
Rationale and Design of the VITALITY-HFpEF Trial. (2019) (25)
Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea. (2018) (25)
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA‐HF trial (2021) (25)
Effects of selective carotid body stimulation with adenosine in conscious humans (2016) (25)
Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial (2015) (25)
Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy (2021) (25)
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial (2022) (25)
Proteomic diversity of high‐density lipoprotein explains its association with clinical outcome in patients with heart failure (2018) (25)
Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. (2017) (25)
What does the lay public know about heart failure? Findings from the Heart Failure Awareness Day Initiative (2016) (25)
Expression and Complex Formation of MMP9, MMP2, NGAL, and TIMP1 in Porcine Myocardium but Not in Skeletal Muscles in Male Pigs with Tachycardia-Induced Systolic Heart Failure (2013) (24)
Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF (2018) (24)
COVID‐19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology (2021) (24)
Activation of the NF‐κB system in peripheral blood leukocytes from patients with chronic heart failure (2005) (24)
Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets (2019) (24)
Population of Polish patients participating in the Heart Failure Pilot Survey (ESC-HF Pilot). (2013) (24)
Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study (2016) (23)
Effect of Empagliflozin on Cardiovascular and Kidney Outcomes in Patients with Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial (2021) (23)
Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: first‐in‐human clinical trial (2021) (23)
Plasma biomarkers to predict or rule out early post‐discharge events after hospitalization for acute heart failure (2017) (23)
Vitamin B12 and folate deficiency in chronic heart failure (2014) (23)
Heart Failure in Patients With Atrial Fibrillation Is Associated With a High Symptom and Hospitalization Burden: The RealiseAF Survey (2013) (23)
Japanese-Western consensus meeting on biomarkers. (2011) (23)
European silver paper on the future of health promotion and preventive actions, basic research, and clinical aspects of age-related disease. (2008) (22)
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial (2022) (22)
Corrigendum to ‘ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008’ [Eur Heart J 2008;29:2388–2442 and Eur J Heart Fail 2008;10:933–989] (2008) (22)
Non‐adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT (2016) (22)
Pharmacotherapy in patients with stable coronary artery disease treated on an outpatient basis in Poland. Results of the multicentre RECENT study. (2008) (22)
Excessive ventilation during early phase of exercise: A new predictor of poor long‐term outcome in patients with chronic heart failure (2007) (21)
Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high‐risk acute heart failure patients (2020) (21)
Impact of periodic breathing on measurement of oxygen uptake and respiratory exchange ratio during cardiopulmonary exercise testing. (2002) (21)
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index (2021) (21)
Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations (2021) (21)
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction (2021) (21)
Value of serum pregnancy-associated plasma protein A for predicting cardiovascular events among patients presenting with cardiac chest pain (2013) (21)
Reproducibility of heart rate variability indices during exercise stress testing and inotrope infusion in chronic heart failure patients. (1996) (21)
RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers (2012) (21)
Circulating testosterone and estradiol, autonomic balance and baroreflex sensitivity in middle-aged and elderly men with heart failure (2013) (21)
European cardiac resynchronization therapy survey II: rationale and design. (2015) (21)
Development of porcine model of chronic tachycardia-induced cardiomyopathy. (2011) (21)
Plasma biomarkers to predict or rule out early post-discharge events in patients discharged after an acute heart failure hospital admission (2017) (21)
Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy. (2015) (21)
Questions and Answers on Diagnosis and Management of Patients with Peripheral Arterial Diseases: A Companion Document of the 2017 ESC Guidelines for the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). (2017) (20)
Temporal trends in secondary prevention in myocardial infarction patients discharged with left ventricular systolic dysfunction in Poland (2018) (20)
Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial (2021) (20)
Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF (2021) (20)
Anemia in heart failure: an overview of current concepts. (2011) (20)
Costs of management of patients with coronary artery disease in Poland: the multicenter RECENT study. (2012) (20)
Echocardiographic determinants of mortality in patients >67 years of age with chronic heart failure. (2000) (20)
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials (2021) (20)
Hepatorenal dysfunction identifies high‐risk patients with acute heart failure: insights from the RELAX‐AHF trial (2019) (20)
Both iron excess and iron depletion impair viability of rat H9C2 cardiomyocytes and L6G8C5 myocytes. (2016) (19)
Heart failure in COVID‐19: the multicentre, multinational PCHF‐COVICAV registry (2021) (19)
Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF (2021) (19)
CHA2DS2‐VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm (2016) (19)
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF (2022) (19)
Cognitive Decline Over Time in Patients With Systolic Heart Failure: Insights From WARCEF. (2019) (19)
Pathophysiological and clinical relevance of simplified monitoring of nocturnal breathing disorders in heart failure patients (2009) (19)
Atrial fibrillation in outpatients with stable coronary artery disease: results from the multicenter RECENT study. (2015) (19)
Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure (2017) (18)
Cardiovascular stress biomarker assessment of middle-aged non-athlete marathon runners (2018) (18)
Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF (2016) (18)
Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial. (2011) (18)
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. (2021) (18)
Low Lymphocyte Ratio as a Novel Prognostic Factor in Acute Heart Failure: Results from the Pre-RELAX-AHF Study (2010) (18)
Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR‐HF substudy (2019) (18)
Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment (2018) (18)
Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function (2010) (18)
Effects of serelaxin in patients admitted for acute heart failure: a meta‐analysis (2019) (18)
Benefit of Warfarin Compared With Aspirin in Patients With Heart Failure in Sinus RhythmClinical Perspective (2013) (17)
Role of Catecholamines and Sympathetic Activation as a Risk Factor for Coronary Artery Disease (1995) (17)
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF (2022) (17)
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure (2021) (17)
Safety, Tolerability and efficacy of Rapid Optimization, helped by NT‐proBNP and GDF‐15, of Heart Failure therapies (STRONG‐HF): rationale and design for a multicentre, randomized, parallel‐group study (2019) (17)
Characteristics of patients with coronary artery disease managed on an outpatient basis in the population of Poland. Results of the multicentre RECENT trial. (2007) (17)
Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF (2011) (16)
New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment (2017) (16)
Evaluación económica de la utilización de hierro carboximaltosa en pacientes con deficiencia de hierro e insuficiencia cardiaca crónica en España (2015) (16)
Acute heart failure: lessons learned, roads ahead (2018) (16)
Prediction of AF in Heart Failure With Preserved Ejection Fraction: Incremental Value of Left Atrial Strain. (2021) (16)
Nocturnal periodic breathing is an independent predictor of cardiac death and multiple hospital admissions in Heart failure (2006) (16)
Higher serum phosphorus is associated with catabolic/anabolic imbalance in heart failure (2015) (16)
Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan. (2009) (16)
Coronary angiography in worsening heart failure: determinants, findings and prognostic implications (2017) (16)
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF (2022) (16)
The first prognostic model for stroke and death in patients with systolic heart failure. (2016) (16)
Cognitive Function in Ambulatory Patients with Systolic Heart Failure: Insights from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial (2014) (16)
Guía de práctica clínica de la ESC sobre revascularización miocárdica, 2014 (2015) (16)
Elevated troponin I level assessed by a new high-sensitive assay and the risk of poor outcomes in patients with acute heart failure. (2017) (15)
Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia. (2016) (15)
Relationship between central sleep apnea and Cheyne-Stokes Respiration. (2016) (15)
Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction (2020) (15)
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF (2020) (15)
European silver paper on the future of health promotion and preventive actions, basic research, and clinical aspects of age-related disease (2009) (15)
Could gonadal and adrenal androgen deficiencies contribute to the depressive symptoms in men with systolic heart failure? (2016) (15)
Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry (2021) (15)
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF (2021) (15)
Clinical, respiratory, haemodynamic, and metabolic determinants of lactate in heart failure. (2018) (14)
[Coordinated heart failure care in Poland: towards optimal organisation of the health care system]. (2018) (14)
Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX‐AHF‐2 trial (2020) (14)
Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline‐directed medical therapy in heart failure with reduced ejection fraction (2021) (14)
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. (2021) (14)
Influence of the availability of iron during hypoxia on the genes associated with apoptotic activity and local iron metabolism in rat H9C2 cardiomyocytes and L6G8C5 skeletal myocytes. (2016) (14)
Hospitalisation length and prognosis in heart failure patients. (2016) (14)
Chemoreceptor-Baroreceptor Interactions in Cardiovascular Disease (2000) (14)
Lack of decrease in plasma N-terminal pro-brain natriuretic peptide identifies acute heart failure patients with very poor outcome. (2008) (14)
Transvenous Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea: Five-Year Safety and Efficacy Outcomes (2021) (13)
Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. (2019) (13)
Oxygenation pattern and compensatory responses to hypoxia and hypercapnia following bilateral carotid body resection in humans (2021) (13)
Management of chronic cardiorenal syndrome. (2010) (13)
Is acute heart failure a distinctive disorder? An analysis from BIOSTAT‐CHF (2020) (13)
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial (2021) (13)
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction (2022) (13)
What's new in the European Society of Cardiology 2016 Guidelines for the diagnosis and treatment of acute and chronic heart failure? (2016) (13)
Nuclear factor-kappaB activity in peripheral blood mononuclear cells in cachectic and non-cachectic patients with chronic heart failure. (2007) (13)
Iron Depletion Affects Genes Encoding Mitochondrial Electron Transport Chain and Genes of NonOxidative Metabolism, Pyruvate Kinase and Lactate Dehydrogenase, in Primary Human Cardiac Myocytes Cultured upon Mechanical Stretch (2018) (12)
Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study (2020) (12)
Acute Heart Failure Clinical Drug Development: From Planning to Proof of Activity to Phase III (2010) (12)
Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure (2017) (12)
The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure. (2018) (12)
Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation (2019) (11)
Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial (2017) (11)
Comparison of clinical profile and management of outpatients with heart failure with reduced left ventricular ejection fraction treated by general practitioners and cardiologists in contemporary Poland: the results from the DATA-HELP registry. (2014) (11)
2016 ESC guidelines for the diagnosis and treatment of atrial fibrillation developed in collaboration with the EACTS (2017) (11)
Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea: A Pooled Cohort Analysis. (2019) (11)
Effects of an outpatient intervention comprising nurse‐led non‐invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (AMULET study): a randomised controlled trial (2021) (11)
Acute heart failure in the young: Clinical characteristics and biomarker profiles. (2016) (11)
Clinical characteristics and predictors of in-hospital mortality in 270 consecutive patients hospitalised due to acute heart failure in a single cardiology centre during one year. (2011) (11)
Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure (2020) (11)
Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology (2022) (11)
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial (2022) (11)
Large animal models of heart failure. (2010) (11)
Long-term time-course of nocturnal breathing disorders in heart failure patients (2009) (11)
280 Body composition and prognosis in 511 chronic heart failure patients: results from three European centers (2004) (11)
Elevated lactate in acute heart failure patients with intracellular iron deficiency as identifier of poor outcome. (2019) (11)
Coronary collateral circulation is less developed when ischaemic heart disease coexists with diabetes. (2003) (11)
The role of exercise ventilation in clinical evaluation and risk stratification in patients with chronic heart failure. (2003) (11)
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial (2022) (11)
Long-term outcome of conservatively treated patients with borderline coronary lesions--role of the fractional flow reserve measurement. (2005) (11)
Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial (2017) (10)
Guidance on the management of left ventricular assist device (LVAD) supported patients for the non‐LVAD specialist healthcare provider: executive summary (2021) (10)
Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure. (2021) (10)
Could an analysis of mean corpuscular volume help to improve risk stratification in non-anemic patients with acute myocardial infarction? (2015) (10)
On the search for the right definition of heart failure with preserved ejection fraction. (2020) (10)
Iron deficiency and cardiovascular disease (2022) (10)
European Silver Paper. Documento europeo sobre el futuro de la promoción de la salud y las acciones preventivas, la investigación básica y los aspectos clínicos de las enfermedades relacionadas con el envejecimiento (2009) (10)
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. (2021) (10)
Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study. (2020) (10)
Increased body fat is associated with potentiation of blood pressure response to hypoxia in healthy men: relations with insulin and leptin (2016) (10)
P-wave signal-averaged electrocardiogram in patients with idiopathic mitral valve prolapse syndrome and supraventricular arrhythmias. (1995) (10)
Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). (2021) (10)
Mega‐trials in heart failure: effects of dilution in examination of new therapies (2020) (10)
Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial. (2016) (10)
The effect of digoxin on the serum potassium concentration. (1993) (10)
Evaluation of Skeletal Muscle Function and Effects of Early Rehabilitation during Acute Heart Failure: Rationale and Study Design (2018) (10)
Comparison of drug-eluting stents to bare-metal stents in ST-elevation myocardial infarction in long-term follow-up. (2013) (9)
Cardiorenal syndromes--recommendations from clinical practice guidelines: the cardiologist's view. (2010) (9)
Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey (ESC-HF Pilot) – Polish population (2015) (9)
Enzyme replacement therapy in Fabry disease in Poland - position statement. (2019) (9)
Rationale and design of CIBIS III (2006) (9)
Elevated plasma endothelin‐1 is related to low natriuresis, clinical signs of congestion, and poor outcome in acute heart failure (2020) (9)
Spot urine sodium in acute heart failure: differences in prognostic value on admission and discharge (2021) (9)
Assessment of baroreflex sensitivity has no prognostic value in contemporary, optimally managed patients with mild‐to‐moderate heart failure with reduced ejection fraction: a retrospective analysis of 5‐year survival (2018) (9)
Monitoring of iron status in patients with heart failure (2019) (9)
Prognostic Value of Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure (CHF) (2008) (9)
Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX‐AHF trial (2017) (9)
Expression of sex steroid receptors and aromatase in adipose tissue in different body regions in men with coronary artery disease with and without ischemic systolic heart failure (2018) (9)
A multi-country randomised trial of the role of a new telemonitoring system in CHF: the HHH study (Home or Hospital in Heart Failure). Rational, study design and protocol (2004) (9)
Distinct clinical phenotypes of congestion in acute heart failure: characteristics, treatment response, and outcomes (2020) (9)
Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure　- Subanalysis of the WARCEF Trial. (2016) (9)
Activation of the NF-kappaB system in peripheral blood leukocytes from patients with chronic heart failure. (2005) (9)
Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea: A Pooled Cohort Analysis. (2019) (9)
The influence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure. (2016) (9)
Iron Deficiency Treatment in Patients with Heart Failure. (2017) (9)
Chemoreflexes in heart failure. (1997) (9)
Safety and efficacy of istaroxime in patients with acute heart failure‐related pre‐cardiogenic shock – a multicentre, randomized, double‐blind, placebo‐controlled, parallel group study (SEISMiC) (2022) (9)
Matrix metalloproteinase 9/neutrophil gelatinase associated lipocalin/tissue inhibitor of metalloproteinasess type 1 complexes are localized within cardiomyocytes and serve as a reservoir of active metalloproteinase in porcine female myocardium. (2014) (9)
Treatment of anemia with darbepoetin alfa in heart failure. (2010) (9)
Iron de ﬁ ciency and cardiovascular disease (2022) (9)
Iron limitation promotes the atrophy of skeletal myocytes, whereas iron supplementation prevents this process in the hypoxic conditions (2018) (9)
Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients (2021) (9)
Impact of periodic breathing on V(O2) and V(CO2): a quantitative approach by Fourier analysis. (1999) (9)
Persistent hyperlactataemia is related to high rates of in-hospital adverse events and poor outcome in acute heart failure. (2019) (8)
Determinants of physical fitness in males with systolic heart failure. (2010) (8)
Persistent high NTpro-BNP concentration as a negative prognostic factor in patients with decompensated heart failure. (2006) (8)
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction (2022) (8)
Measurement of fractional flow reserve in patients with multi-vessel coronary artery disease and borderline lesions prevents unnecessary revascularisation procedures. (2004) (8)
Genetic risk and atrial fibrillation in patients with heart failure (2020) (8)
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. (2022) (8)
Hypoxic tachycardia is not a result of increased respiratory activity in healthy subjects (2019) (8)
HFA of the ESC position paper on the management of LVAD‐supported patients for the non‐LVAD specialist healthcare provider Part 3: at the hospital and discharge (2021) (8)
Clinical characteristics and methods of treatment of patients with stable coronary heart disease in the primary care settings – the results of the Polish, multicentre Angina Treatment Pattern (ATP) study (2004) (8)
271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF (2020) (8)
[Assessment of the functioning of autonomic nervous system in the context of cardiorespiratory reflex control]. (2010) (8)
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency (2022) (8)
Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction (2022) (8)
Abnormal serum calcium levels are associated with clinical response to maximization of heart failure therapy. (2015) (8)
Novel IVC Doraya Catheter Provides Congestion Relief in Patients With Acute Heart Failure (2022) (8)
[Coping styles in patients with systolic heart failure]. (2013) (7)
Distinct renin/aldosterone activity profiles correlate with renal function, natriuretic response, decongestive ability and prognosis in acute heart failure. (2021) (7)
Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. (2015) (7)
Effects of running a marathon on irisin concentration in men aged over 50 (2018) (7)
Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. (2021) (7)
Patterns of dyspnoea onset in patients with acute heart failure: clinical and prognostic implications (2018) (7)
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial (2022) (7)
Heart rate and blood pressure monitoring in heart failure (2019) (7)
True worsening renal function identifies patients with acute heart failure with an ominous outcome. (2019) (7)
ORGINAL ARTICLE Persistent high NTpro-BNP concentration as a negative prognostic factor in patients with decompensated heart failure (2006) (7)
Iron deficiency in heart failure: Impact on response to cardiac resynchronization therapy. (2016) (7)
Linee guida ESC per la diagnosi e il trattamento dello scompenso cardiaco acuto e cronico 2008 = Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 (2009) (7)
Human carotid bodies as a therapeutic target: new insights from a clinician's perspective. (2018) (7)
Association between mortality and implantable cardioverter‐defibrillators by aetiology of heart failure: a propensity‐matched analysis of the WARCEF trial (2019) (7)
Anabolic deficiencies in men with systolic heart failure: do co-morbidities and therapies really contribute significantly? (2013) (7)
Stroke in Heart Failure in Sinus Rhythm: The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction Trial (2013) (7)
URSODEOXYCHOLIC ACID IN PATIENTS WITH CHRONIC HEART FAILURE. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER TRIAL (2012) (6)
Biomarkers of Myocardial Injury and Remodeling in Heart Failure (2022) (6)
Serum phosphorus level is related to degree of clinical response to up-titration of heart failure pharmacotherapy. (2014) (6)
EPO's rescue mission in acute myocardial infarction: still more hopes than evidence. (2010) (6)
The effects of chronic implanted transvenous phrenic nerve stimulation in central sleep apnea: The remede(R) System pilot study (2013) (6)
Andropausal syndrome in men with systolic heart failure. (2013) (6)
Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX‐AHF‐2 study (2020) (6)
Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial. (2022) (6)
Anemia and congestive heart failure. (2003) (6)
Comprehensive Heart Failure Care pilot study: starting point and expected developments. (2019) (6)
Acute hyperoxia reveals tonic influence of peripheral chemoreceptors on systemic vascular resistance in heart failure patients (2021) (6)
CUPID 2: A Phase 2b Trial Investigating the Efficacy and Safety of the Intracoronary Administration of AAV1/SERCA2a in Patients with Advanced Heart Failure (2015) (6)
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. (2021) (6)
The Effects of a Marathon Effort on Psychomotor Performance and Catecholamine Concentration in Runners over 50 Years of Age (2020) (6)
Novel Phenotyping for Acute Heart Failure—Unsupervised Machine Learning-Based Approach (2022) (6)
[New oral anticoagulants in the prevention of embolic complications in patients with atrial fibrillation. Polish Cardiac Society, Polish Neurological Society and Working Group on Haemostasis of the Polish Society of Haematologists and Transfusiologists consensus statement]. (2012) (6)
Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST‐AHF trial (2018) (6)
Review article Psychological aspects of heart failure – beyond depression, anxiety and quality of life (2015) (6)
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial (2022) (6)
Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2. (2020) (6)
Primary Human Cardiomyocytes and Cardiofibroblasts Treated with Sera from Myocarditis Patients Exhibit an Increased Iron Demand and Complex Changes in the Gene Expression (2021) (5)
Borderline coronary lesions may lead to serious coronary events--long-term outcome in 65 conservatively treated patients. (2005) (5)
Testosterone deficiency in men with heart failure: pathophysiology and its clinical, prognostic and therapeutic implications. (2014) (5)
CENTRAL SLEEP APNEA EVENTS ARE TERMINATED BY PHRENIC NERVE STIMULATION (2010) (5)
DAPAGLIFLOZIN IMPROVES OUTCOMES IRRESPECTIVE OF NT-PROBNP CONCENTRATION IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL (2020) (5)
Sex hormone-binding globulin and heart failure: a passive carrier of steroid hormones or an active hormone itself? (2009) (5)
Corrigendum to ‘Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology’ [Eur J Heart Fail 2018;20:3–15] (2018) (5)
Increased gene expression of catecholamine-synthesizing enzymes in adrenal glands contributes to high circulating catecholamines in pigs with tachycardia-induced cardiomyopathy. (2015) (5)
Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure (2022) (5)
Iohexol clearance is superior to creatinine-based renal function estimating equations in detecting short-term renal function decline in chronic heart failure (2015) (5)
Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX‐AHF trial (2017) (5)
Association of quality of life with anticoagulant control in patients with heart failure: the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial. (2014) (5)
Late‐onset hypogonadism in men with systolic heart failure: prevalence, clinical associates, and impact on long‐term survival (2014) (5)
Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device‐supported patients for the non‐left ventricular assist device specialist healthcare provider: Part 2: at the emergency department (2021) (5)
‘Iron deficiency: an ominous sign in patients with systolic chronic heart failure’ [Eur Heart J 2010;31:1872–1880, doi:10.1093/eurheartj/ehq158] (2011) (5)
Nurse‐led ambulatory care supported by non‐invasive haemodynamic assessment after acute heart failure decompensation (2021) (5)
[The effect of sotalol hydrochloride therapy on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation]. (1996) (5)
[Depression in patients with chronic heart failure]. (2008) (5)
Psychological Gender of Men With Systolic Heart Failure (2014) (5)
Heart failure not enough pump iron? (2011) (5)
Sunday, 26 August 2012 (2012) (5)
Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure (2018) (5)
Pathophysiology of Advanced Heart Failure: What Knowledge Is Needed for Clinical Management? (2021) (5)
Neutrophil-to-Lymphocyte Ratio and Outcomes in Patients Admitted for Acute Heart Failure (As Seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF Studies). (2022) (5)
Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF. (2022) (5)
Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF) (2022) (5)
HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non‐hospital settings in the community (2021) (4)
Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial: VICTORIA Outcomes Model. (2021) (4)
Insulin‐like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence (2022) (4)
The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-atrial natriuretic peptide and mid-region pro-adrenomedullin in patients with acute dyspnea (2012) (4)
Impact of digoxin on risk of death in heart failure patients treated with b-blockers. Results from Polish part of ESC Heart Failure Long-Term Registry. (2018) (4)
Globulina transportadora de hormonas sexuales: ¿un transportador pasivo de hormonas esteroideas o una molécula hormonal activa en la insuficiencia cardiaca? (2009) (4)
Clinically overt infections and markers of inflammation in patients admitted to Emergency Department due to high-energy discharges of implantable cardioverter-defibrillator (2018) (4)
Estrogen replacement therapy normalizes the autonomic control of the cardiovascular system in menopausal women (1996) (4)
Comparison of left ventricular longitudinal systolic function parameters in the prediction of adverse outcome in heart failure with preserved ejection fraction (2021) (4)
Clinical implications of low estimated protein intake in patients with heart failure (2022) (4)
Demographic and clinical characteristics of patients with atrial fibrillation and cardioversion as planned therapeutic options in the International Registry on Cardioversion of Atrial Fibrillation RHYTHM-AF Polish substudy. (2014) (4)
Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure. (2021) (4)
sGC Stimulators and Activators (2019) (4)
Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF (2022) (4)
225 Symptoms, functional status, and quality of life in patients with controlled and uncontrolled atrial fibrillation. Data from the cross-sectional REALISE-AF registry (2012) (4)
Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from the BIOSTAT‐CHF study (2021) (4)
[Rehabilitation and models of domiciliary care of patients with chronic heart failure: preliminary results of the HHH study]. (2005) (4)
Validation of transurethral intra‑abdominal pressure measurement in acute heart failure. (2018) (4)
Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF (2022) (4)
Vasodilators in Acute Heart Failure (AHF) (2009) (4)
Cardiac emergencies during the COVID-19 pandemic in the light of the current evidence. (2020) (4)
EFFECTS OF INTRAVENOUS IRON THERAPY IN IRON DEFICIENT PATIENTS WITH SYSTOLIC HEART FAILURE: META-ANALYSIS OF RANDOMIZED CONTROL TRIALS (2015) (4)
Nordic Walking May Safely Increase the Intensity of Exercise Training in Healthy Subjects and in Patients with Chronic Heart Failure. (2016) (4)
Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction. (2021) (4)
Renal failure in patients with heart failure - analysis based on ESC-HF Pilot survey (2013) (4)
Looking at the heart failure through the prism of liver dysfunction (2020) (4)
Measurement of coronary fractional flow reserve. Standard doses of intracoronary adenosine are insufficient to induce maximal hyperaemia. (2003) (4)
Acute heart failure: diagnosis (2018) (4)
A multi-country randomised trial of the role of a new telemonitoring system in CHF: the HHH Study (Home or Hospital in Heart Failure). Preliminary data (2005) (4)
Heart failure classifications - guidelines. (2010) (4)
Central Chemoreceptor Sensitivity Is Not Enhanced in Contemporary Patients With Chronic Systolic Heart Failure Receiving Optimal Treatment. (2017) (4)
679 Reduction in serum testosterone deteriorates exercise capacity in men in the course of chronic heart failure (2007) (4)
Empagliflozin in patients hospitalized for acute heart failure. (2022) (4)
IMPROVED SURVIVAL IN PATIENTS WITH DIASTOLIC HEART FAILURE DISCHARGED ON BETA-BLOCKER AND ACE INHIBITORS (2013) (4)
[Arterial baroreflex--physiological role and assessment of functioning]. (2013) (3)
Benefit of Warfarin Compared with Aspirin in Heart Failure Patients in Sinus Rhythm: A Subgroup Analysis of WARCEF, a Randomized Controlled Trial Homma et al: WARCEF Subgroup Analysis (2017) (3)
581 Iron deficiency is a common finding in patients with stable chronic heart failure (2006) (3)
Cardiac emergencies during the coronavirus disease 2019 pandemic in the light of the current evidence (2020) (3)
Sex differences in porcine left ventricular myocardial remodeling due to right ventricular pacing (2015) (3)
Special Japanese-Western Consensus Meeting on Biomarkers Executive Summary (2011) (3)
Targeting Iron Deficiency in Heart Failure (2021) (3)
Drug therapy in elderly heart failure patients (2019) (3)
The Role of Pharmacological Treatment in the Chemoreflex Modulation (2022) (3)
Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure (2021) (3)
Iron deficiency in heart failure - 2020 update. (2019) (3)
[Use of body surface heart potential mapping for registration of electrical phenomenal in the atrium]. (1996) (3)
Cardioversion of Atrial Fibrillation (RHYTHM-AF) International Registry in Poland. (2014) (3)
[Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation]. (1995) (3)
Chronotropic response during exercise and recovery in men with mild systolic chronic heart failure. (2010) (3)
Changes in Dyspnea during Treatment of Acute Heart Failure Are Correlated with Clinical Signs, Rehospitalizations and Mortality. Results from the Pre-RELAX-AHF Trial (2009) (3)
Abnormal indices of autonomic function are no longer predictors of poor outcome in diabetic patients without neuropathy but with coexisting coronary artery disease who receive optimal pharmacological therapy. (2009) (3)
Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design. (2021) (3)
Phrenic Nerve Stimulation Improves Circulatory Delay in Patients With Heart Failure and Central Sleep Apnea (2012) (3)
Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients: From the WARCEF Trial. (2017) (3)
Rationale and design of the AMULET study: A new Model of telemedical care in patients with heart failure (2021) (3)
Early Hemodynamic Changes following Surgical Ablation of the Right Greater Splanchnic Nerve for the Treatment of Heart Failure with Preserved Ejection Fraction (2022) (3)
[Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement]. (2016) (3)
Resting Heart Rate and Ischemic Stroke in Patients with Heart Failure (2017) (3)
Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation (2022) (3)
The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. (2021) (3)
Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency (2022) (3)
Current and emerging pharmacologic options for the management of patients with chronic and acute decompensated heart failure (2017) (3)
10 year trends in hospitalization rates due to heart failure and related in‐hospital mortality in Poland (2010–2019) (2020) (3)
Not all fluid overloads are the same: some practical considerations for better decongestion (2021) (3)
Proportional pulse pressure relates to cardiac index in stabilized acute heart failure patients (2018) (3)
Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial (2022) (3)
Pooled safety analysis of darbepoetin alfa in the treatment of symptomatic heart failure (2008) (3)
Treatment of advanced chronic heart failure with normal left ventricular ejection fraction. Response to the letter by Dr. Martinez‐Selles (2007) (3)
Cardioversion differences among first detected episode, paroxysmal, and persistent atrial fibrillation patients in the RHYTHM AF registry in Poland. (2015) (3)
Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure (2022) (3)
580 Anaemia in men with chronic heart failure: an element of multiple anabolic depletion (2006) (3)
Treatments targeting inotropy A position paper of the Committees on Translational Research and Acute Heart Failure of the Heart Failure Association of the European Society of Cardiology (2019) (3)
COVID-19 Related Myocarditis in Adults: A Systematic Review of Case Reports (2022) (3)
[Differentiation between vegetation and lead associated thrombus - role of PET scan in difficult diagnostic process]. (2010) (3)
Long-term survival and nearly asymptomatic course of carcinoid tumour with multiple metastases (treated by surgery, chemotherapy, (90)Y-DOTATATE, and LAR octreotide analogue): a case report. (2009) (3)
Effect of carvedilol on exercise tolerance in patients with chronic heart failure and a restrictive left ventricular filling pattern. (2003) (3)
Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial). (2018) (3)
Monday, 27 August 2012 (2012) (3)
Abstract 2005: Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Non-anemic Patients with Symptomatic Chronic Heart Failure and Iron Deficiency: A Randomised, Controlled, Observer-blinded Trial (FERRIC-HF) (2006) (3)
Hypoglycaemia in diabetic patients: highly undesirable by cardiologists. (2013) (3)
[Significance of resistance training for the attenuation of skeletal myopathy in chronic heart failure]. (2008) (3)
A new telemonitoring system in heart failure. Preliminary data from the multi-country randomized study HHH (Home or Hospital in Heart failure) (2006) (3)
Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial (2022) (3)
The RELAXin in Acute Heart Failure (RELAX-AHF) Trial (2012) (3)
Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with RAAS-inhibitors-Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology (2018) (3)
Recommendations on the use of innovative medical technologies in cardiology and cardiac surgery and solutions leading to increased availability for Polish patients. (2013) (3)
Usefulness of the P Wave Signal‐Averaged Electrocardiogram in Predicting Patients at Risk of Atrial Flutter and Fibrillation Induced by Transesophageal Pacing (1999) (3)
Corrigendum to: 'Iron deficiency: an ominous sign in patients with systolic chronic heart failure' (2011) (2)
Review article Depression in patients with chronic heart failure (2008) (2)
Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology (2022) (2)
Minimal Clinically Important Difference for Six-minute Walk Test in Patients with HFrEF and Iron Deficiency. (2022) (2)
[The effect of cholinergic stimulation on autonomic balance and immune response in patients with chronic heart failure]. (2007) (2)
P1639Prognostic utility of H2FPEF score in heart failure with preserved ejection fraction (2019) (2)
Extra‐cardiac targets in the management of cardiometabolic disease: Device‐based therapies (2021) (2)
Iron Deficiency in Heart Failure (2019) (2)
Management of patients with heart failure and secondary mitral regurgitation (2020) (2)
EFFECT OF TREATMENT WITH DAPAGLIFLOZIN ACCORDING TO BASELINE SYSTOLIC BLOOD PRESSURE IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL (2020) (2)
TCT-134 Transvenous Phrenic Nerve Stimulation in the Treatment of Central Sleep Apnea in Patients with Reduced Ejection Fraction: A Report from the remede(r) System Pilot Study (2013) (2)
[The role of augmented chemoreceptor sensitivity in the pathophysiology of cardiovascular disease]. (2009) (2)
Catabolic/anabolic imbalance is accompanied by changes of LV steroid nuclear receptor expression in tachycardia-induced systolic heart failure in male pigsSteroid hormones in pig model of heart failure. (2021) (2)
NF-κB expression in mononuclear cells from patients with chronic heart failure observed in endotoxin tolerance (2007) (2)
The story of carotid body resection for HF: How an intriguing pathophysiology concept became a valid target for intervention. (2017) (2)
[Clinical significance and prognostic value of anemia in heart failure patients]. (2007) (2)
Beta-blocker treatment before angiotensin-converting enzyme inhibitor therapy in newly diagnosed heart failure. (2005) (2)
[Cardio-renal syndrome in patients with heart failure: pathophysiology, epidemiology and clinical significance]. (2011) (2)
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF. (2022) (2)
A review from the Biomarkers Working Group of the Heart Failure Association of the ESC: A review from the Biomarkers Working Group of the Heart Failure Association of the ESC. (2022) (2)
Medical emergency team interventions in patients with ST-segment elevation myocardial infarction throughout Poland in 2018. (2020) (2)
Antiplatelets in acute coronary syndrome in Poland – from guidelines to clinical practice (2021) (2)
Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. (2021) (2)
Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society. (2017) (2)
Anaemia (and iron deficiency?) in aortic stenosis—a bystander or a potential therapeutic target? (2015) (2)
[Heart rate profile: from physiology to clinical practice]. (2013) (2)
Increased symptom-improvement with the novel vasodilator, relaxin, in Acute Heart Failure (AHF) patients with elevated blood pressure. Results from the Pre-RELAX-AHF study (2009) (2)
Safety, Feasibility of Controllable Decrease of Vena Cava Pressure by Doraya Catheter in Heart Failure (2023) (2)
Phrenic nerve stimulation in patients with central sleep apnea: a single‑center experience from pilot and pivotal trials evaluating the remedē System. (2019) (2)
Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF (2022) (2)
Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation (2023) (2)
Machine Learning Approach to Understand Worsening Renal Function in Acute Heart Failure (2022) (2)
Clinical profile and management of outpatients with non-ischemic and non-hypertensive systolic heart failure: Analysis of the Polish DATA-HELP registry. (2013) (2)
EFFECT OF TREATMENT WITH DAPAGLIFLOZIN IS CONSISTENT ACROSS THE RANGE OF BODY MASS INDEX IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL (2020) (2)
Serum Osmolarity and Vasopressin Concentration in Acute Heart Failure—Influence on Clinical Course and Outcome (2022) (2)
Prognostic importance of serum troponin concentration in patients with an implanted cardioverter‑defibrillator admitted to the emergency department due to electric shock. (2019) (2)
Time to Treatment and Vasodilator Efficacy in Acute Heart Failure: Results from the Pre-RELAX-AHF Study (2009) (2)
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout (2023) (2)
Changes in parasympathetic system in medulla oblongata in male pigs in the course of tachycardia-induced cardiomyopathy (2013) (2)
[The effect of long term use of amiodarone hydrochloride on time and frequency domain parameters of signal averaged electrocardiogram in patients with ischemia heart disease]. (1997) (2)
The effect of dapagliflozin across the spectrum of baseline risk: a post-hoc analysis of DAPA-HF (2020) (2)
Frailty and cognitive impairment are predictive of takotsubo syndrome following pacemaker implantation (2020) (2)
Intravenous iron supplementation: novel anti-remodelling therapy for patients with heart failure? (2021) (2)
University of Groningen Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency Ponikowski, (2015) (2)
Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure (2022) (2)
Anticoagulation for heart failure patients in sinus rhythm: common in clinical practice but still not evidence-based. (2012) (2)
Intravenous ferric carboxymaltose does not provide benefits in reperfused acute myocardial infarction in the rat with normal iron status. (2021) (2)
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology (2022) (2)
Role of skeletal muscle perfusion and insulin resistance in the effect of dietary sodium on heart function in overweight (2021) (2)
Relationship between the CHA2DS2-VASc score and atrial fibrillation in patients hospitalised due to heart failure. (2019) (2)
Elevated serum lactate is a marker of organ damage related to impaired hemodynamics and indicates poor prognosis in acute heart failure (2013) (2)
Vasodilators in Acute Heart Failure (AHF): Does Blood Pressure Matter? Results from Pre-Relax-AHF (2009) (2)
Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER (2022) (2)
Quality of Anticoagulation Control in Preventing Adverse Events in Heart Failure Patients in Sinus Rhythm: A Warfarin Aspirin Reduced Cardiac Ejection Fraction Trial (WARCEF) Substudy Homma et al: TTR and Outcomes in WARCEF Trial (2016) (2)
Sexual dimorphism in socioeconomic differences regarding the risk factors, symptomatology and management of patients with stable coronary artery disease in Poland. (2015) (2)
Acute heart failure in patients admitted to the emergency department with acute myocardial infarction. (2016) (2)
Erythropoietin — A Novel Therapeutic Option for Cachectic Patients (2005) (2)
Percutaneous reduction of mitral valve regurgitation using the MitraClip system – immediate and 90-day follow-up of 3 cases (2013) (1)
Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose (2013) (1)
Dilemmas on diagnosis and treatment of iron deficiency in patients after an episode of acute heart failure. (2021) (1)
34 Association of physician‐determined worsening heart failure with signs and symptoms, hospitalization duration, and 60‐day outcomes in patients hospitalised for acute heart failure (2008) (1)
Coronary rotational atherectomy in patients with unsuccessful classical angioplasty – in-hospital and six-month follow-up (2012) (1)
Valsalva-derived measures and phenylephrine test in patients with heart failure with reduced ejection fraction receiving comprehensive neurohormonal blockade drug therapy: a 5-year event-free survival analysis. (2021) (1)
MP415EFFECT OF INTRAVENOUS IRON THERAPY WITH FERRIC CARBOXYMALTOSE ON OUTCOMES IN IRON-DEFICIENT PATIENTS WITH RENAL DYSFUNCTION AND HEART FAILURE WITH REDUCED EJECTION FRACTION: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF FOUR RANDOMIZED, DOUBLE-BLIND TRIALS (2017) (1)
[Assessment of chemoreflex involved in reflex cardio-respiratory control]. (2011) (1)
Getting ahead of the game: in-hospital initiation of HFrEF therapies (2022) (1)
TAILORING THERAPY IN ACUTE HEART FAILURE: CAN BIOMARKERS DISTINGUISH RESPONDERS FROM NON-RESPONDERS? (2015) (1)
Pol-tako - the first, nationwide Polish multicenter analysis of patients with takotsubo syndrome. (2021) (1)
BASELINE CARDIAC TROPONIN T, CLINICAL OUTCOMES AND VERICIGUAT TREATMENT EFFECT IN HEART FAILURE WITH REDUCED EJECTION FRACTION STUDY: INSIGHTS FROM THE VICTORIA TRIAL (2021) (1)
Novel Biomarkers of Renal Dysfunction and Congestion in Heart Failure (2022) (1)
Design of the Effect of EMPaglifozin on ExeRcise ability and HF-symptoms, In patients with chronic heArt faiLure (EMPERIAL) trials of empagliflozin in patients with chronic heart failure with reduced or preserved ejection fraction (2019) (1)
Kidney Function After Initiation and Discontinuation of Empagliflozin in Heart Failure Patients With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. (2021) (1)
Clinical and economic impact of ferric carboxymaltose treatment for iron deficiency in patients stabilized following acute heart failure: a multinational study. (2022) (1)
Pulse pressure and prognosis in patients with heart failure with reduced ejection fraction (2019) (1)
Abstract 18230: Iron Deficiency Impairs Exercise Capacity in Patients With Systolic Chronic Heart Failure, Beyond its Negative Effects on Erythropoiesis (2010) (1)
Tuesday, 28 August 2012 (2012) (1)
Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week. (2023) (1)
[Is there a place for treatment with type 5 phosphodiesterase inhibitors in heart failure patients?]. (2011) (1)
CONSISTENT BENEFIT OF DAPAGLIFLOZIN ACCORDING TO BACKGROUND THERAPY IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL (2020) (1)
HIGH SOLUBLE TRANSFERRIN RECEPTOR IN PATIENTS WITH SYSTOLIC HEART FAILURE: A MEASURE OF IRON DEFICIENCY AND A STRONG PREDICTOR OF MORTALITY (2013) (1)
Effects of the new vasodilator relaxin for the treatment of patients with acute heart failure and normal to elevated blood pressure: results of a phase 2b study (Pre-RELAX-AHF) (2009) (1)
37 Combined testosterone and insulin‐like growth factor deficiency impairs quadriceps strength in men with chronic heart failure (2008) (1)
Highlights of the 2006 scientific sessions of the European Society of Cardiology: Barcelona, Spain, September 2-5, 2006. (2006) (1)
QUALITY OF LIFE 60 DAYS AFTER AN ACUTE HEART FAILURE EVENT: INSIGHTS FROM THE PROTECT TRIAL (2012) (1)
Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency: Rationale and design of CONFIRM-HF study (2014) (1)
Central Sleep Apnea in Heart Failure Worsens Throughout the Night (2015) (1)
Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy (2020) (1)
689 The activation of the NF-kappaB system in chronic heart failure (2003) (1)
P920The influence of iron status on the impaired functioning of human cardiofibroblasts and cardiomyocytes in the course of acute phase of myocarditis (2018) (1)
Cardiovascular Complications of Viral Respiratory Infections and COVID-19 (2022) (1)
Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. (2022) (1)
FC 021EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY FOLLOWING ACUTE HEART FAILURE, ACCORDING TO BASELINE EGFR: A SUBGROUP ANALYSIS OF THE AFFIRM-AHF TRIAL (2021) (1)
251Cardiovascular hospitalisation and death by subgroup in iron-deficient patients with heart failure treated with intravenous ferric carboxymaltose: an individual patient meta-analysis (2017) (1)
Chronic heart failure. The relationship between increased activity of skeletal muscle ergoreceptors and reduced exercise tolerance. (2004) (1)
Hemoglobin, anemia, and clinical outcomes in vericiguat global study in subjects with heart failure with reduced ejection fraction (VICTORIA) (2021) (1)
Vitamin b12 and folate deficiency: prevalence, clinical correlates and outcome in chronic heart failure (2014) (1)
Beta-3 Receptor Agonists (2019) (1)
Editorial comment on effect of exercise training in patients with heart failure (2004) (1)
SOTAGLIFLOZIN REDUCES TOTAL HOSPITALIZATIONS AND INCREASES DAYS ALIVE AND OUT OF HOSPITAL IN THE SOLOIST-WHF TRIAL (2021) (1)
Guía de práctica clínica para la valoración del riesgo cardiaco preoperatorio y el manejo cardiaco perioperatorio en la cirugía no cardiaca. Version corregida 03/03/2010 (2009) (1)
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved (2022) (1)
Artículo especialGuía de práctica clínica para la valoración del riesgo cardiaco preoperatorio y el manejo cardiaco perioperatorio en la cirugía no cardiaca1 (2009) (1)
Amended STRONG‐HF study design (2021) (1)
Single Night Transvenous Phrenic Nerve Stimulation Improves Central Sleep Apnoea In Systolic Heart Failure (2011) (1)
Anticoagulación para pacientes con insuficiencia cardiaca en ritmo sinusal, habitual en la práctica clínica. pero aún no basada en la evidencia (2012) (1)
Myosin Activators (2019) (1)
Intravenous ferric carboxymaltose improves quality of life in patients with chronic heart failure and iron deficiency regardless the presence of anaemia: an analysis from the FAIR-HF study (2010) (1)
Inflammatory activation biomarker profile after marathon running and its impact on cardiovascular stress in amateur middle-aged male runners. (2022) (1)
InterAtrial Shunt Device (IASD®) implantation - a novel treatment method for heart failure with preserved ejection fraction. (2017) (1)
[Recording of atrial and ventricular signal averaged ECGs in patients with mitral valve prolapse syndrome]. (1998) (1)
Efficacy of intravenous ferric carboxymaltose for iron deficiency following acute heart failure (AHF) in patients with previously diagnosed HF: a subgroup analysis of AFFIRM-AHF (2021) (1)
The ergoreflex activity during exercise: Predictor of impaired heart rate variability in chronic heart failure (2000) (1)
Abstract 16353: Effects of Dapagliflozin on Physical and Social Activity Limitations in Patients With Heart Failure and Reduced Ejection Fraction: An Analysis of DAPA-HF (2020) (1)
Impact of mitral regurgitation in patients with acute heart failure: insights from the RELAX‐AHF‐2 trial (2023) (1)
[European Silver Paper. European document on the future of health promotion and preventive measures, basic research and clinical aspects of aging-related diseases]. (2009) (1)
Clinical determinants and prognostic significance of hypocapnia in acute heart failure (2022) (1)
IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF. (2022) (1)
Predictors of inappropriate shocks from implantable cardioverter-defibrillators. (2019) (1)
[Application of levosimendan in acute heart failure patients with symptoms of low cardiac output: case series report]. (2013) (1)
Predictors of Outcome in Acute Stroke Patients: Are They Reliable and Potentially Useful? (2017) (1)
Novel Therapeutic Devices in Heart Failure (2022) (1)
[Characteristics of ischemic heart disease patients with late ventricular potentials]. (1995) (1)
Iron deficiency as an emerging therapeutic target in patients stabilized after an episode of acute heart failure (2021) (1)
542 Pentoxifylline improves the haemoglobin levels in anaemic patients with chronic heart failure (2007) (1)
Intravenous Iron Sucrose in Anemic and Non-anemic Iron Deficient Patients with CHF: A Randomized, Controlled, Observer-blinded Intervention Study (FERRIC-HF) (2006) (1)
CHA2DS2-VASC SCORE AND ADVERSE EVENTS IN PATIENTS WITH HEART FAILURE AND SINUS RHYTHM (2016) (1)
Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. (2018) (1)
Contribution of Peripheral Chemoreceptors to Exercise Intolerance in Heart Failure (2022) (1)
N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes (1)
Abstract 17913: Linear Relationship Between Seattle Heart Failure Model Predicted Mortality and Hospitalizations in Patients with Chronic Heart Failure (2011) (1)
[Can beta-blockers become first-line therapy in chronic heart failure?]. (2006) (0)
Long-term survival and nearly asymptomatic course of carcinoid tumour with multiple metastases (treated by surgery, chemotherapy, 90 Y-DOTATATE, and LAR octreotide analogue) — a case report Długotrwałe przeżycie i niemal bezobjawowy przebieg rakowiaka z mnogimi przerzutami (leczonego metodą chirurgi (2009) (0)
Association between Left Ventricular Ejection Fraction and Worsening Renal Function in Acute Heart Failure: Insights from the RELAX-AHF-2 Trial (2019) (0)
Eje PCSK9-receptor de LDL y resultados clínicos en la insuficiencia cardiaca: un subanálisis del estudio BIOSTAT-CHF (2018) (0)
Apparent Non-Cited Overlap between Two Published Articles by the Same Group of Authors (2010) (0)
University of Dundee Using matrix assisted laser desorption ionisation mass spectrometry ( MALDI-MS ) profiling in order to predict clinical outcomes of patients with heart failure (2018) (0)
[A 67-year-old men with not corrected tetralogy of Fallot]. (2013) (0)
Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients with Pre Cardiogenic Shock. (2023) (0)
NT-PROBNP DURING SCREENING IN THE STUDY OF VERICIGUAT IN PARTICIPANTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (VICTORIA) TRIAL: INSIGHTS INTO OUTCOMES AND VERICIGUAT (2023) (0)
506 Reduced bone mineral density in men with chronic heart failure and its pathophysiological mechanisms (2004) (0)
Stroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk model (2022) (0)
Pressure-Volume Profiles in Heart Failure Across Sexes and Phenotypes. (2022) (0)
[Mortality studies in heart failure. The role of ACE inhibitors becomes more important]. (1991) (0)
Iron availability and the expression of genes of oxidative and non-oxidative metabolic pathways in primary human cardiac myocytes cultured upon mechanical stretch (2017) (0)
The blunted loop diuretic response in acute heart failure is driven by reduced tubular responsiveness rather than insufficient tubular delivery. (2023) (0)
Czy istnieją przesłanki, by stosować testosteron u mężczyzn z przewlekłą niewydolnością serca? Are there premises to supplement testosterone in men with chronic heart failure? (2008) (0)
Abstract 16374: Effect of Dapagliflozin According to Duration of Heart Failure: An Analysis of the DAPA-HF Trial (2020) (0)
Muscle Ergoreflex Activity and Autonomic Balance Assessed in the Vertical and Horizontal Body Positions in Young Healthy Men (2017) (0)
Relationship of Dapagliflozin WithSerumSodium (2022) (0)
P-445 Abnormal heart rate turbulence predicts episodes of ventricular tachycardia in patients with implantable cardioverter-defibrillator (2003) (0)
CA125 IN PATIENTS WITH HFREF AND THE EFFECT OF DAPAGLIFLOZIN: INSIGHTS FROM DAPA-HF (2023) (0)
Incremental value of myocardial work in predicting beneficial response to aortic valve replacement in patients with aortic stenosis (2022) (0)
Effects of running a marathon on irisin concentration in men aged over 50 (2018) (0)
258 12-week resistance training improves exercise capacity and muscle strength in patients with chronic heart failure, without any effect on heart structure assessed using standard echocardiography (2005) (0)
Iron Deficiency and Deranged Myocardial Energetics in Heart Failure (2022) (0)
Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction. (2023) (0)
Role of left atrial strain response to exercise in the transition from the preclinical to overt heart failure (2022) (0)
Low-dose dopamine improves ventilatory efficiency during exercise in heart failure with preserved ejection fraction through inhibition of tonic activity of peripheral chemoreceptors (2022) (0)
Health Status Across Major Subgroup of Patients with Heart Failure and Preserved Ejection Fraction. (2023) (0)
EMPULSE: Empagliflozin delivers rapid and clinically meaningful decongestion (2022) (0)
University of Dundee The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure Bayes-Genis, (2017) (0)
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause (2022) (0)
Troponin Release in Patients Admitted with Acute Decompensated Heart Failure and Renal Dysfunction: Results from the Pilot Phase of the PROTECT Trial (2009) (0)
Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLASTâ•’AHF trial (2019) (0)
644 Depletion in more than one endocrine anabolic axis identifies men with chronic heart failure of particularly high long‐term mortality (2006) (0)
NSS_A_300713 515..526 (2021) (0)
PREVALENCE, PREDICTORS AND PROGNOSIS OF IRON DEFICIENCY IN PATIENTS WITH CHRONIC HEART FAILURE (2012) (0)
Inhibition of peripheral chemoreceptors improves ventilatory efficiency during exercise in heart failure with preserved ejection fraction − a role of tonic activity and acute reflex response (2022) (0)
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association ( HFA ) of the ESC (2023) (0)
University of Dundee Non-cardiac Comorbidities in Heart Failure with Reduced , Mid-range and Preserved Ejection (2018) (0)
Iron deficiency in patients with chronic kidney disease requiring hemodialysis: do inflammation and overexpressed hepcidin contribute significantly? (2013) (0)
GROWTH DIFFERENTIATION FACTOR-15, CLINICAL OUTCOMES, AND THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: INSIGHTS FROM THE DAPA-HF TRIAL (2023) (0)
Role of dietary sodium restriction in chronic heart failure. Systematic review and meta-analysis. (2023) (0)
Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis. (2023) (0)
56-70: CRT Survey II (2016) (0)
Association of Atrial Fibrillation on Rest and Exercise Hemodynamics in Heart Failure with Mid-Range and Preserved Ejection Fraction (2017) (0)
Effect of Intravenous Iron Replacement on Recurrent Heart Failure Hospitalizations and Cardiovascular Mortality in Patients with Heart Failure and Iron Deficiency: A Bayesian Meta-Analysis. (2023) (0)
Sex differences in porcine left ventricular myocardial remodeling due to right ventricular pacing (2015) (0)
THE NF‐KAPPAB SYSTEM IS OVERACTIVATED IN IMMUNOCOMPETENT CELLS IN PATIENTS WITH CHRONIC FAILURE: 185 (2004) (0)
Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure (2018) (0)
THE EFFECT OF DAPAGLIFLOZIN ON INSULIN INITIATION OR INTENSIFICATION IN PATIENTS IN HEART FAILURE AND DIABETES: A POOLED ANALYSIS OF DAPA-HF AND DELIVER (2023) (0)
582 Bone status and bone loss over time in men with chronic heart failure, and their clinical and hormonal determinants (2006) (0)
Impact of marathon performance on muscles stiffness in runners over 50 years old (2023) (0)
141Determinants of iron deficiency in younger versus older patients with heart failure (2017) (0)
Chapter 28 Renal support therapy (2010) (0)
CARDIAC FAILURE EDITOR-IN-CHIEF (2009) (0)
Iron Therapy (2019) (0)
Worsening renal function in acute heart failure: change in BP and effects of relaxin (2009) (0)
Cardiomyocytes and myocyte cells contain the molecular system of intracellular iron metabolism and respond to environmental iron changes in in vitro conditions (2014) (0)
[Are there premises to supplement testosterone in men with chronic heart failure?]. (2008) (0)
[Clinical use of ventilation measurement during early phase of exercise in patients with chronic heart failure]. (2004) (0)
Hemosiderin Accumulation in Liver Decreases Iron Availability in Tachycardia-Induced Porcine Congestive Heart Failure Model (2022) (0)
Subject Index Vol. 116, 2010 (2010) (0)
ORIGINAL PAPER Fractional flow reserve measurement in patients with multivessel coronary artery disease and borderline lesions prevents unnecessary revascularization procedures: results of the 3.5-year follow-up (2005) (0)
Expression of α7 Nicotinic ACh Receptors in Blood Mononuclear Cells: Correlation with Impaired Baroreflex Sensitivity in Patients with Heart Failure (2018) (0)
Late-onset hypogonadism in men with systolic heart failure: prevalence, clinical associates, and impact on long-term survival: Late-onset hypogonadism in heart failure (2014) (0)
P4353Iron status, respiratory muscle strength, and physical fitness in men with heart failure with reduced ejection fraction (2017) (0)
[Patient with the intervention of an implantable cardioverter-defibrillator in a hospital emergency department]. (2018) (0)
P935 Association of intracellular iron status with left ventricular systolic function response to exercise in heart failure with preserved ejection fraction (2020) (0)
Heart failure - a challenge of the XXI century. Need for the introduction of a new healt-care system model (2004) (0)
677 Does andropause exist in men with chronic heart failure, and is it linked to multiple anabolic deficiency ? (2007) (0)
The Relationship between LVEF and Cardiovascular Outcomes Following Hospitalization for Heart failure: Insights from the RELAX-AHF-2 Trial (2019) (0)
Exaggerated blood pressure response at mild exertional intensity is associated with lower exercise capacity and worsening of cardiac structural and functional profile (2020) (0)
Transvenous Phrenic Nerve Stimulation Effectiveness is Sustained at 18 Months: Data From the Remede System Pivotal Trial (2017) (0)
P3195Impaired functioning and low mass of skeletal muscles in men with heart failure with reduced ejection fraction are reflected by reduced muscle-derived irisin (2018) (0)
351 Systemic activation of skeletal muscle ergoreceptors is associated with the progression of the syndrome of chronic heart failure (2006) (0)
Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF (2022) (0)
Assessment of ventilatory response to exercise in patients with chronic heart failure (2002) (0)
Burden of multimorbidity in a Polish cohort of ambulatory and hospitalized heart failure patients from two large European registry programs: prognostic implications. (2021) (0)
550 In chronic heart failure elevated homocysteine level is related to impaired metabolism and endothelial dysfunction (2003) (0)
Reduced muscle-derived irisin reflects low muscles mass and impaired functioning of skeletal muscles in men with heart failure with reduced ejection fraction (2018) (0)
245 Prognostic utility of growth‐differentiation factor‐15 in patients with chronic heart failure (2007) (0)
Does right ventricular pacing increase the risk of ventricular arrhythmias in patients with an implantable cardioverter-defibrillator? (2014) (0)
EMPAGLIFLOZIN IN PATIENTS HOSPITALIZED FOR DE NOVO VERSUS DECOMPENSATED CHRONIC HEART FAILURE: INSIGHTS FROM THE EMPULSE TRIAL (2022) (0)
Low ventilatory responsiveness to transient hypoxia or breath-holding predicts fast marathon performance in healthy middle-aged and older men (2021) (0)
Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial (2021) (0)
Gender-related differences in the clinical characteristics, pharmacotherapy and outcomes in the one-year follow-up in the Polish population of heart failure pilot survey (2013) (0)
446 Endotoxin in vitro stimulates proliferation of peripheral blood mononuclear cells in patients with mild stable chronic heart failure, whereas in oedematous patients promotes apoptosis (2004) (0)
Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure (2022) (0)
CORONARY ARTERY DISEASE AND CARDIOVASCULAR OUTCOMES IN HEART FAILURE: INSIGHTS FROM THE VERICIGUAT GLOBAL STUDY IN SUBJECTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (VICTORIA) TRIAL (2021) (0)
Contemporary Pharmacological Treatment of Heart Failure (2016) (0)
Adenosine Receptor Agonists (2019) (0)
Increase in heart failure mortality in Poland: can we explain the reasons? (2014) (0)
The in fl uence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure (2016) (0)
University of Groningen Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure (2018) (0)
Plasma biomarkers to determine individual response to rolofylline in acute heart failure: results from the PROTECT trial (2017) (0)
Ferric Carboxymaltose in Iron Deficient Patients Admitted for Acute Heart Failure (2020) (0)
Vericiguat and health status outcomes in heart failure with reduced ejection fraction: insights from the VICTORIA trial (2021) (0)
P-446 Heart rate turbulence triggered by paced premature ventricular contractions in patients with implantable cardioverter-defibrillator (2003) (0)
Clinical practice guidelines of the ESC on myocardial revascularization, 2014 (2015) (0)
Hematinics in Patients with Complicated Acute Myocardial Infarction: Results from an OPTIMAAL Substudy (2008) (0)
Non-invasive approach for the assessment of sympathetic baroreflex function: A feasibility study (2017) (0)
Abstract 14472: Iron Deficiency Plays an Important Prognostic Role in the Cardiorenal Anemia Axis: A Pooled Multicenter Analysis (2013) (0)
Cardiac resynchronisation therapy in heart failure patients with ischaemic vs non-ischaemic aetiology : results from 11088 patients in the ESC CRT Survey II (2018) (0)
Intravenous iron therapy and circulating biomarkers of inflammation in men with heart failure with reduced ejection fraction (2020) (0)
Sympathetic activation and malignant ventricular arrhythmias: a molecular link? (2002) (0)
Zespoły sercowo−nerkowe u chorych z niewydolnością serca: patofizjologia, epidemiologia, znaczenie kliniczne Cardio-renal syndrome in patients with heart failure: pathophysiology, epidemiology and clinical significance (2011) (0)
Prognosis in Diastolic Heart Failure (2008) (0)
Treating in-stent restenosis with drug-eluting balloon with intracoronary ultrasound control, with later optical coherent tomography control (2010) (0)
[BNP - new prognostic parameter in acute coronary syndromes?]. (2003) (0)
348 Muscle ergoreflex contribution to the respiratory control is active during both upper and lower limb exercise in heart failure patients (2003) (0)
4880How does diabetes affect iron status in patients with heart failure (2017) (0)
Re: Pacing, takotsubo syndrome, and transient rise of pacing threshold: What is the mechanism? (2020) (0)
Patient-reported dyspnea in acute heart failure trials. Use of the Likert and the visual analog scales in the pre-RELAX AHF study (2009) (0)
[Clinical significance of atrial signal-averaged electrocardiogram in patients with electrically-induced paroxysmal atrial fibrillation]. (1997) (0)
Review article Are there premises to supplement testosterone in men with chronic heart failure (2008) (0)
Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF (2022) (0)
[Effect of sildenafil on haemodynamic parameters of pulmonary circulation and physical capacity in patients with systolic chronic heart failure with secondary severe pulmonary hypertension]. (2011) (0)
Abstract 17546: Effect of Intravenous Ferric Carboxymaltose on Symptoms and Quality of Life in Iron-Deficient Patients With Chronic Heart Failure With and Without Anemia: A Sub-Analysis of the FAIR-HF Trial (2010) (0)
Induction of Day-Time Periodic Breathing is Associated With Augmented Reflex Response From Peripheral Chemoreceptors in Male Patients With Systolic Heart Failure (2022) (0)
[Heart failure in every-day practice. Can we improve the results of treatment?]. (2002) (0)
[The effects of long-term treatment of sotalol hydrochloride on time and frequency domain parameters of signal averaged electrocardiogram in patients with ischemic heart disease]. (1996) (0)
Prediction of Post-Discharge Outcomes for Patients Hospitalized with Heart Failure: Results from PROTECT (2015) (0)
The activation of the NF-κB system in chronic heart failure (2003) (0)
The effect of dapagliflozin in patients with HFrEF and COPD: a post-hoc analysis of DAPA-HF (2020) (0)
350 Oscillatory ventilation during exercise: independent predictor of increased mortality in patients with stable chronic heart failure (2006) (0)
Dynamics of left ventricular mass over time in patients with chronic heart failure with and without cardiac cachexia (2000) (0)
Clopidogrel in Atrial Fibrillation: Is There Any Justification Now in the Era of New Anticoagulants? (2012) (0)
537CRT in women- results from the ESC CRT Survey II with 11 088 patients (2018) (0)
Chloroquine and hydroxychloroquine for the prevention and therapy of COVID-19: new hopes and old cardiovascular concerns. (2020) (0)
Hemoglobin independently predicts exercise capacity in anemic patients with chronic heart failure (2003) (0)
Myocardial iron content in non‐ischaemic cardiomyopathy: how much is known? (2020) (0)
Advances in Clinical Trials (2016) (0)
857 Serum hepcidin is not linked to iron status in patients with chronic heart failure (2007) (0)
Symptoms associated with male aging in men with systolic heart failure (2013) (0)
Iconography : Echocardiographic determinants of mortality in patients >67 years of age with chronic heart failure (2011) (0)
128 Clinical impact of changes in mitral regurgitation severity after optimization of medical therapy in heart failure: insights from BIOSTAT-CHF (2021) (0)
472 Feasibility of home telemonitoring of vital signs and cardiorespiratory signals in chronic heart failure patients: preliminary results from the HHH study (2005) (0)
The interrelation between renal function and the efficacy of initial monotherapy with bisoprolol or enalapril followed by their combination in patients with heart failure - results of CIBIS-III (2006) (0)
The PROTECT In-Hospital Risk Model (2011) (0)
The PROTECT In-Hospital Risk Model: 7-Day Outcome in Patients Hospitalized with Acute Heart Failure (AHF) and Renal Dysfunction (2011) (0)
Potassium and the use of RAAS inhibitors in Heart Failure 5 with reduced ejection fraction : data from BIOSTAT-CHF 6 (2017) (0)
Relationship of Vascular Endothelial Growth Factor C, a Lymphangiogenesis Modulator, with Edema Formation, Congestion and Outcomes in Acute Heart Failure. (2023) (0)
P-R interval in porcine model of chronic tachycardia-induced cardiomyopathy (2013) (0)
Prognostic value of the MAGGIC score, H2FPEF score and HFA-PEFF algorithm in patients with exertional dyspnea and the incremental value of exercise echocardiography. (2022) (0)
[Strategies of preoperative evaluation and risk reduction in patients undergoing invasive procedures in the view of recent European Society of Cardiology guidelines]. (2010) (0)
Design and Rationale of the Soluble Guanylate Cyclase Stimulator in Heart Failure Studies (SOCRATES) (2014) (0)
Abstract 19027: Influence of Intravenous Ferric Carboxymaltose on Health-Related Quality of Life Measures in Patients with Chronic Heart Failure and Iron Deficiency: an Analysis from the FAIR-HF Study (2010) (0)
The future of health promotion and preventative actions, basic research, and clinical aspects of age-related disease. A report of the european summit on age related disease (2009) (0)
Effect of Implantable Cardioverter-Defibrillators by Etiology of Heart Failure: A Propensity-Matched Mortality Analysis of the WARCEF Trial (2018) (0)
Attitude towards knowledge of the disease and psychological characteristics of patients with systolic heart failure (2017) (0)
Kidney Function After Initiation And Discontinuation Of Empagliflozin (EMPA) In Heart Failure (HF) Patients (Pts) With And Without Type 2 Diabetes (T2D): Insights From The Emperial Trials (2020) (0)
University of Groningen Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure (2017) (0)
37 THE IMPORTANCE OF PHYSICAL TRAINING AND RELAXATION TECHNIQUES IN THE TREATMENT OF MALES WITH HEART FAILURE AGED 60-YEARS (2012) (0)
FORUM MŁODYCH Postinfarction ventricular septum rupture complicated with cardiogenic shock, requiring reoperation (2012) (0)
229 Effects of rolofylline, a new adenosine A1 receptor antagonist, on symptoms, renal function and outcomes in patients with acute heart failure. Results of the PROTECT pilot study (2008) (0)
[Transient myocardial ischemia in patients after myocardial infarction and late cell potentials]. (1997) (0)
PREVALENCE, PREDICTORS AND PROGNOSIS OF IRON DEFICIENCY IN PATIENTS WITH CHRONIC HEART FAILURE : AN INTERNATIONAL POOLED ANALYSIS OF 1,506 PATIENTS (2012) (0)
Abstract 12021: Changes in Troponin I and Outcomes in Acute Heart Failure: Data from the Pre-RELAX study (2012) (0)
567 Adrenal and gonadal andropenia is related to clinical severity and increased mortality in men with chronic heart failure (2004) (0)
University of Groningen Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure (2017) (0)
Co-morbidity (HFrEF and HFpEF): anaemia/iron deficiency (2018) (0)
Contents Vol. 116, 2010 (2010) (0)
Zastosowanie lewosimendanu u chorych z ostrą niewydolnością serca z objawami małego rzutu minutowego serca: opis serii przypadków Application of levosimendan in acute heart failure patients with symptoms of low cardiac output: case series report (2013) (0)
P588Effects of phrenic nerve stimulation on central sleep apnea in heart failure patients (2017) (0)
257 Mid‐regional pro‐adrenomedullin as a novel and prognostic marker in chronic heart failure (CHF) (2006) (0)
P1541Inflammatory activation biomarker profile after marathon run and its impact on cardiovascular stress biomarker release in amateur middle-aged male runners (2017) (0)
Seat belts‐related behaviors in car drivers with cardiac implantable electronic devices (2019) (0)
Impact of Long-term Endurance Performance on Muscles Stiffness in Marathon Runners Over 50 Years Old (2021) (0)
Case report CoreValve transcatheter aortic valve implantation complicated by stress cardiomyopathy (tako-tsubo) and septic shock (2012) (0)
549 In chronic heart failure overactive chemokine system is associated with immune activation, low grade inflammation and predicts loss of fat tissue (2003) (0)
Issue Information (2020) (0)
976-11 Cyclical Variation in the Occurrence of Paroxysmal Supraventricular Tachycardia in Female Patients (1995) (0)
358 Ergoreflex contribution to ventilatory response assessed during exercise of forearm and quadriceps muscles in patients with chronic heart failure (2003) (0)
[The influence of ischemia provoked by dobutamine and exercise on presence of late potentials in patients after myocardial infarction]. (1998) (0)
Worsening Renal Function in Acute Heart Failure: Change in Blood Pressure and Effects of Relaxin (2009) (0)
Patients with a Mid-Range Ejection Fraction (2017) (0)
Central and Peripheral Determinants of Exercise Capacity in Heart Failure PatientsWith Preserved Ejection Fraction (2019) (0)
Age, Clinical Characteristics and Outcomes of Patients With Acute Decompensated Heart Failure: Insights from the PROTECT Trial (2012) (0)
Gimpelewicz, C. et al. (2017) Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: a subgroup analysis (2017) (0)
Abstract 16662: GDF-15: Association With Pulmonary Hemodynamic Indices and Reduction With Serelaxin in Acute Heart Failure (2014) (0)
[Heart failure--challenge of the 21st century. Need for introducing a new model of the health-care system]. (2004) (0)
Management of Chronic Heart Failure – Update 2013 (2013) (0)
P3650Trends in prevention after acute myocardial infarction in patients with reduced left ventricle ejection fraction in Poland (2017) (0)
Contribution of iron status to malfunctioning of human cardiomyocytes and cardiofibroblasts in the course of myocarditis (2018) (0)
Patients With Stable Chronic Heart Failure Impaired Insulin Sensitivity as an Independent Risk Factor for Mortality in (2011) (0)
Late Cardiac Tamponade as a Result of Parietal Pericardium Erosion. (2015) (0)
Low-dose dopamine infusion increases baroreflex sensitivity by inhibition of peripheral chemoreflex (2013) (0)
In chronic heart failure the ergoreflex activity to exercise is a predictor of impaired heart rate variability (1998) (0)
332 Nocturnal periodic breathing oxygen desaturations and mortality in heart failure patients (2008) (0)
MP417IMPACT OF INTRAVENOUS FERRIC CARBOXYMALTOSE IRON THERAPY ON SYMPTOMS AND FUNCTIONALITY IN IRON-DEFICIENT PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND RENAL DYSFUNCTION: AN INDIVIDUALPATIENT DATA META-ANALYSIS OF 4 RANDOMIZED, DOUBLE-BLIND TRIALS (2017) (0)
1108-117 Reduced bone mass in men with advanced chronic heart failure is accompanied by hyperparathyroidism, andropenia, and inflammation, and predicts poor outcome (2004) (0)
Considerable Regional Variation in AAV1 Neutralizing Antibodies and Its Consequences for a Multinational Clinical Trial of Gene Transfer for Advanced Heart Failure: The CUPID 2 Experience (2014) (0)
343 Depression in men with chronic heart failure: prevalence and hormone determinants (2007) (0)
40 LOW LEVEL OF PHYSICAL FITNESS IS A PREDICTOR OF POOR PROGNOSIS IN MEN WITH STABLE HEART FAILURE (2012) (0)
P754Iron status indices (transferrin saturation, serum ferritin) in the course of acute myocarditis: relations with neurohormonal activation, cardiac dysfunction and clinical recovery (2019) (0)
[Intracardiac thrombi in pulmonary embolism of a priori non high risk: therapeutic dilemma]. (2013) (0)
Abstract 3767: Bone Mineral Density and Bone Loss over Time in Men with Chronic Heart Failure, and their Determinants (2006) (0)
CONFIRM-HF: Novel Approach Treating ID Improved Function, Symptoms, and QOL (2014) (0)
279 Prevalence of complex anabolic deficiency, and its relationships with clinical status and prognosis in men with chronic heart failure (2005) (0)
Coronary flow reserve: a new target for treating hypertension (2009) (0)
Associations of Body Mass Index with Laboratory and Biomarkers in Acute Heart Failure Patients (2017) (0)
Contents Vol. 40, No. 4, 2015 (2015) (0)
Iron status, catabolic/anabolic balance, and skeletal muscle performance in men with heart failure with reduced ejection fraction. (2020) (0)
International Differences in Acute Heart Failure (AHF) Patients : Insight from the PROTECT Trial (2011) (0)
Functional limitation and exercise hyperventilation are associated with oscillatory ventilation on exercise in chronic heart failure (1998) (0)
Abstract 16682: Regional Differences in Heart Failure Medication Changes During Acute Heart Failure Hospitalization: Findings From the PROTECT Trial (2013) (0)
Abstract 2904: Deficiency in Circulating Testosterone Predicts Reduction in Exercise Capacity in Men in the Course of Chronic Heart Failure (2007) (0)
Effect of short-term rapid ventricular pacing followed by pacing interruption on arterial blood pressure in healthy pigs and pigs with tachycardiomyopathy. (2014) (0)
Dopamine withdrawal causes chemoreflex-related increase in minute ventilation (2013) (0)
[Early bioprosthetic mitral valve thrombosis]. (2012) (0)
[The role of skeletal muscle ergoreceptors in chronic heart failure]. (2004) (0)
139Determinants of true worsening renal function and its prognostic meaning in patients with acute heart failure (2017) (0)
Insulin resistance and survival in chronic heart failure (2003) (0)
Kompleksowa protekcja mikrokrążenia wieńcowego podczas pierwotnej angioplastyki u pacjenta z zawałem serca Complex embolic protection during primary percutaneous coronary intervention (2011) (0)
[The influence of organic myocardial damage on parameters of signal-averaged electrocardiogram in patients with electrically-induced atrial fibrillation]. (1996) (0)
1033-117 Ventilatory response to early phase of exercise: An useful index for comprehensive clinical assessment of patients with heart failure and novel predictor of prognosis (2004) (0)
Periodic breathing in chronic heart failure is associated with severe autonomic impairment and increased peripheral chemosensitivity (1997) (0)
Erratum to: Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial (2017) (0)
252Cardiovascular and renal outcomes in iron-deficient patients with HFrEF and renal dysfunction treated with i.v. ferric carboxymaltose: An individual patient data meta-analysis (2017) (0)
Corrigendum to "Trimetazidine in cardiovascular medicine," [Int. J. Cardiol., 293 (2019) 39-44]. (2020) (0)
Abstract 13207: The First Prognostic Model for Stroke and Death in Patients With Systolic Heart Failure (2013) (0)
473 Sexual complaints in men with chronic heart failure: prevalence and hormone determinants (2008) (0)
Deficiency: FERRIC-HF: A Randomized, Controlled, Observer-Blinded Trial Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and (2011) (0)
Changes in Iron Status in Peripheral Blood and Livers of Pigs with Tachycardia-Induced Cardiomyopathy (2017) (0)
Abstract 16392: The Effect of Dapagliflozin on Anemia in Patients With Heart Failure and Reduced Ejection Fraction: An Analysis of DAPA-HF (2020) (0)
Award winning ceremony: best paper prize and student awards 2015/2016. ICE Kraków Congress Centre, Kraków, Poland. (2016) (0)
Czy jest miejsce na terapię inhibitorami fosfodiesterazy typu 5 u chorych z niewydolnością serca? Is there a place for treatment with type 5 phosphodiesterase inhibitors in heart failure patients? (2011) (0)
The short-term benefit from nurse-led ambulatory care supported by non-invasive haemodynamic assessment in patients after acute heart failure decompensation depends on time since hospital discharge. (2021) (0)
308 Periodic breathing is frequent during the daytime in stable patients with heart failure and is related to impaired exercise tolerance and abnormal autonomic reflex control (2004) (0)
532 Anemia is independent predictor of poor outcome in patients with chronic heart failure (2003) (0)
Abstract 18661: Results of Chronic Phrenic Nerve Stimulation using the RespiCardia(TM) System are Comparable to Acute Results in the Improvement of Central Sleep Apnea: First in Man Experience (2010) (0)
The Win Ratio Method in Heart Failure Trials: Lessons Learnt From Empulse. (2023) (0)
Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF. (2023) (0)
5222Muscle-derived follistatin and decorin levels in men with heart failure with reduced ejection fraction and different iron status (2018) (0)
P6353Iron depletion in human cardiomyocytes cultured with sera from myocarditis patients (2019) (0)
Do Cheyne and Stokes have an important message for modern‐day patients with heart failure? Yes, they do (2020) (0)
Impaired left ventricular filling predicts augmented ventilatory response to exercise in patients with chronic heart failure (2002) (0)
[Percutaneous removal of a broken central venous catheter from the right atrium]. (2011) (0)
[The influence of exercise and dobutamine-induced ischemia on the presence of late potentials in patients after myocardial infarction]. (1997) (0)
Insulin Sensitivity as an ndependent Risk Factor for Mortality in atients With Stable Chronic Heart Failure (2016) (0)
Hypercapnic Chemosensitivity in Patients with Heart Failure: Relation to Shifts in Type-1 Insulin-Like Growth Factor and Sex Hormone-Binding Globulin Levels (2013) (0)
P325Incremental value of left atrial strain in predicting atrial fibrillation in heart failure with preserved ejection fraction (2019) (0)
75 Oscillatory ventilation at rest coexisting with increased ventilatory response to exercise allow to identify heart failure patients with very poor outcome (2007) (0)
P1392 Association of iron deficiency with left ventricular longitudinal function abnormalities in patients with acute myocarditis (2020) (0)
Heart Failure with Preserved left ventricular Ejection Fraction (HFPEF) in the Polish population of the ESC EURObservational research programme: the heart failure pilot registry (2013) (0)
253Effect of i.v. ferric carboxymaltose iron therapy on symptoms and functional status in iron-deficient patients with HFrEF and renal dysfunction: An individual patient data meta-analysis (2017) (0)
Phrenic Nerve Simulation for Central Sleep Apnea is Effective and Safe in the Presence of Concomitant Cardiac Devices (2018) (0)
renal syndrome in patients with heart failure : pathophysiology , epidemiology and clinical significance (2011) (0)
642 Mid-regional pro-atrial natriuretic peptide (MR-proANP) better than N-terminal Pro B-type natriuretic peptide (NT-proBNP) predicts survival in patients with chronic heart failure (CHF) (2006) (0)
Prevalence of Central Sleep Apnea in Patients Screened During the remedē® System Pilot Study (2014) (0)
[Exercise rehabilitation in patients with heart failure--palliation or disease modification?]. (1996) (0)
030 - In Heart Failure Patients with CSA, Stimulation of the Phrenic Nerve Improves Sleep and Quality of Life (2017) (0)
310 Increased number of CD4+ T cells in the peripheral blood in patients with chronic heart failure (2004) (0)
Not Enough Pump Iron (2011) (0)
Abstract 18883: High Sensitivity Troponin T in Acute Heart Failure: Insights from RELAX-AHF (2014) (0)
Muscle Ergoreflex Activity and Autonomic Balance Assessed in the Vertical and Horizontal Body Positions in Young Healthy Men (2017) (0)
Impact of admission serum osmolarity on decongestion rate and clinical outcomes in patients with acute heart failure (2022) (0)
Expression of α7 Nicotinic ACh Receptors in Blood Mononuclear Cells: Correlation with Impaired Baroreflex Sensitivity in Patients with Heart Failure (2018) (0)
POSB132 Ferric Carboxymaltose for the Treatment of Iron Deficiency in Patients with Acute Heart Failure with Reduced Ejection Fraction: Events Avoided and Cost Savings from the Perspective of Healthcare Payers in the United States (2022) (0)
EE326 Alleviating the Burden of Iron Deficiency in Heart Failure: A Multinational European Study (2022) (0)
POSC131 Events Avoided and Cost Savings Associated with the Use of Intravenous Ferric Carboxymaltose for the Treatment of Iron Deficiency in Patients Stabilized after an Acute Heart Failure Episode with Reduced Ejection Fraction in the UK (2022) (0)
EE60 An Economic Evaluation of Introducing Ferric Carboxymaltose for the Treatment of Iron Deficiency in Patients With Heart Failure From the Perspective of Healthcare Payers in Sweden, Germany, France, Poland and Spain (2022) (0)
Association of physician-determined worsening heart failure with signs and symptoms, hospitalization duration, and 60-days outcomes in patients hospitalised for acute heart failure. (2008) (0)
POSB133 Translating Findings from Affirm-AHF: Events Avoided and Cost Savings Associated with the Use of Ferric Carboxymaltose for the Treatment of Iron Deficiency in Patients with Acute Heart Failure with Reduced Ejection Fraction in Italy (2022) (0)
HFWM: Sera from myocarditis patients caused iron depletion in culturedhuman cardiomyocytes (2019) (0)
Elevated markers of liver function are associated with poorer outcomes in HFREF: an analysis of DAPA-HF (2021) (0)
respiratory muscle strength, and physical ﬁtness in men with heart failure with reduced ejection associated with the severity of cardiac of diabetic (0)
HETEROGENEITY IN EFFICACY OF ROLOFYLLINE USING A RISK-BASED EVALUATION IN PATIENTS HOSPITALIZED WITH ACUTE HEART FAILURE (2016) (0)
Hypercapnic Chemosensitivity in Patients with Heart Failure: Relation to Shifts in Type-1 Insulin-Like Growth Factor and Sex Hormone-Binding Globulin Levels (2013) (0)
Heart failure and diabetes: a treacherous combination 1023 HEART FAILURE AND DIABETES: A TREACHEROUS COMBINATION 4879 | BEDSIDE Heart failure with mid range ejection fraction, characteristics and prognosis in patients with and without type 2 diabetes (0)
OP-EHEA180728 4269..4276 (2018) (0)
Oscillatory ventilation during exercise: A marker of functional limitation in chronic heart failure (2000) (0)
POSA130 Events Avoided and Cost Savings Associated with Ferric Carboxymaltose Treatment of Iron Deficiency in Patients with Acute Heart Failure with Reduced Ejection Fraction from the Perspective of Healthcare Payers in Switzerland (2022) (0)
Wpływ stymulacji cholinergicznej na równowagę autonomiczną i układ immunologiczny w niewydolności serca The effect of cholinergic stimulation on autonomic balance and immune response in patients with chronic heart failure (2007) (0)
[Complex embolic protection during primary percutaneous coronary intervention]. (2011) (0)

This paper list is powered by the following services:

Other Resources About Piotr Ponikowski

en.wikipedia.org

What Schools Are Affiliated With Piotr Ponikowski?

Piotr Ponikowski is affiliated with the following schools:

Piotr Ponikowski's Academic­Influence.com Rankings

Why Is Piotr Ponikowski Influential?

Piotr Ponikowski's Published Works

Published Works

Other Resources About Piotr Ponikowski

What Schools Are Affiliated With Piotr Ponikowski?

Piotr Ponikowski's AcademicInfluence.com Rankings